

10.12.2019

12:30 - 13:30	Type: Coffee break Title: Lunch	Room K
13:30 - 17:40	Type: Educational session Title: Joint SITC-ESMO Immunotherapy Primer (LIMITED AVAILABILITY) Moderation: Emanuela Romano, FR; Kim Margolin, US; Bernard Fox, US	Room K
13:30 - 13:30	DOI session	
13:30 - 14:00	T-cell, B-cell, and NK cell biology <u>D. Speiser</u> , Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), Lausanne, CH	
14:00 - 14:30	DC-based immunology and antigen presentation <u>T. De Gruijl</u> , University Medical Center Amsterdam - Cancer Center Amsterdam, Amsterdam, NL	
14:30 - 14:40	Break	
14:40 - 15:10	Cytokines and small molecules <u>K. Margolin</u> , City of Hope Comprehensive Cancer Center, Duarte, US	
15:10 - 15:40	Tumour microenvironment and immune cell exclusion <u>E. Romano</u> , Institut Curie, Paris, FR	
15:40 - 16:10	Coffee break	
16:10 - 16:40	Adoptive cellular therapies and bispecifics <u>U. Petrausch</u> , OnkoZentrum Zürich, Zurich, CH	
16:40 - 17:10	Biomarkers <u>B. Fox</u> , Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US	
17:10 - 17:40	Panel discussion <u>B. Fox</u> ¹ , <u>K. Margolin</u> ² , ¹ Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US, ² City of Hope Comprehensive Cancer Center, Duarte, US	

11.12.2019

09:00 - 10:30	Type: Educational session Title: Introduction to immunotherapy in cancer I Moderation: Pedro Romero, CH; John Haanen, NL	Room A
09:00 - 09:00	DOI session	
09:00 - 09:20	Understanding the basics of immunotherapy <u>A. Furness</u> , The Royal Marsden NHS Foundation Trust, London, GB	
09:20 - 09:40	Immunomodulation through immune-checkpoints <u>A. Curioni</u> , University Hospital Zürich, Zurich, CH	
09:40 - 10:00	Cancer vaccines <u>B. Szabados</u> , Barts Cancer Institute-Queen Mary University of London, London, GB	
10:00 - 10:20	Cell therapies against cancer <u>M. Donia</u> , Herlev Hospital - National Center for Cancer Immune Therapy, Herlev, DK	
10:20 - 10:30	General discussion / Q&A	
10:30 - 11:00	Type: Coffee break Title: Coffee break	Foyer ABC

11:00 - 12:15 **Type: Educational session** **Room A**
Title: Introduction to immunotherapy in cancer II
 Moderation: Kim Margolin, US; Bernard Fox, US; John Haanen, NL; Pedro Romero, CH

11:00 - 11:00 **DOI session**

11:00 - 11:20 **Targeting co-inhibitory receptors for immunotherapy of cancer**
E. Romano, Institut Curie, Paris, FR

11:20 - 11:40 **New tools to prevent cancer growth and spread: A clever approach**
M. Hollmén, University of Turku Faculty of Medicine, Turku, FI

11:40 - 12:00 **Immune cell functional diversity understood through single cell transcriptomics**
A. Van Der Leun, Netherlands Cancer Institute, Amsterdam, NL

12:00 - 12:15 **General discussion / Q&A**

12:15 - 12:45 **Type: Coffee break** **Foyer ABC**
Title: Welcome reception

12:45 - 13:00 **Type: Educational session** **Room A**
Title: Opening session
 Moderation: Pedro Romero, CH; John Haanen, NL

12:45 - 12:45 **DOI session**

13:00 - 13:45 **Type: Keynote** **Room A**
Title: Opening Keynote lecture
 Moderation: John Haanen, NL

13:00 - 13:00 **DOI session**

13:00 - 13:45 **Status of CAR T-cells for cancer**
C. June, University of Pennsylvania- Clinical Research Building, Philadelphia, US

14:00 - 15:30	Type: Educational session Title: Adoptive cell therapy for precision targeting of cancer Moderation: John Haanen, NL; Sine Reker Hadrup, DK	Room A
14:00 - 14:00	DOI session	
14:00 - 14:20	Cell therapy with tumour infiltrating lymphocytes <u>P. Hwu</u> , MD Anderson Cancer Center, Houston, US	
14:20 - 14:40	CAR T-cells for the treatment of solid tumours <u>S. Guedan</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
14:40 - 15:00	Cell therapy with TCR-engineered T-cells <u>H. Stauss</u> , UCL Cancer Institute - UCL - London's Global University, London, GB	
15:00 - 15:20	Novel tools to investigate safety and efficacy for T-cell therapy <u>S. Reker Hadrup</u> , National Veterinary Institute (DTU Vet), Copenhagen, DK	
15:20 - 15:30	General discussion / Q&A	
15:30 - 16:00	Type: Coffee break Title: Coffee break	Foyer ABC

16:00 - 17:30	Type: Educational session Title: Metabolism and metabolomics Moderation: Pedro Romero, CH; Luciana Berod, DE	Room A
16:00 - 16:00	DOI session	
16:00 - 16:20	What intratumoural tregs eat makes them strong and vulnerable <u>P.-C. Ho</u> , Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), Epalinges, CH	
16:20 - 16:40	Metabolic guidance to T-cell differentiation <u>L. Berod</u> , Twincore - Institute of Infection Immunology, Hannover, DE	
16:40 - 17:00	T-cell responses in a hypoxic microenvironment <u>I. Foskolou</u> , University of Cambridge, Cambridge, GB	
17:00 - 17:20	Obesity and anti-obesity interventions on immune-cell mediated anti-tumor responses <u>A. Monir Monjazeb</u> , UC Davis Clinical and Translational Science Center, Sacramento, US	
17:20 - 17:30	General discussion / Q&A	

16:00 - 17:30 **Type: Educational session** **Room C**
Title: New vaccine technologies and administration modalities
Moderation: Thierry de Baere, FR

16:00 - 16:00 **DOI session**

16:00 - 16:20 **How to best predict neoantigens for personalised anti-tumour vaccines?**
R. Yelenksy, Gritstone Oncology, Emeryville, US

16:20 - 16:40 **Addressing heterogeneity: A hot topic**
O. Rekdal, Lytix Biopharma, Oslo, NO

16:40 - 17:00 **Intra-tumor immunotherapy**
T. De Baere, Institut Gustave Roussy, Villejuif, FR

17:00 - 17:20 **Boosting antigen presentation in the tumor: TLR agonists & FLT3 ligand**
J. Brody, Mount Sinai Hospital, New York City, US

17:20 - 17:30 **General discussion / Q&A**

17:30 - 18:00 **Type: Educational session** **Room C**
Title: ESMO Immuno-Oncology Technology (IOTECH)
Moderation: John Haanen, NL

17:30 - 17:35 **Introduction to the journal by its Editor-in-Chief**

17:35 - 17:45 **Presentation of selected manuscripts**

17:45 - 17:55 **Presentation of selected manuscripts**

17:55 - 18:00 **General discussion / Q&A**

12.12.2019

08:45 - 10:15 **Type: Educational session** **Room C**
Title: Diverse functions of innate immune cells in cancer
Moderation: Karin de Visser, NL; Ignacio Melero, ES

08:45 - 08:45 **DOI session**

08:45 - 09:05 **Exploring and exploiting the tumor microenvironment**

J. Joyce, Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), Lausanne, CH

09:05 - 09:25 **NK cells and their check points**

C. Jandus, Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, CH

09:25 - 09:45 **The IL-8 neutrophil collusion against cancer immunotherapy**

I. Melero, Clinica Universitaria de Navarra, Pamplona, ES

09:45 - 10:05 **How the genetic makeup of cancer dictates the immune landscape**

K. De Visser, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

10:05 - 10:15 **General discussion / Q&A**

09:00 - 10:15 **Type: Proffered Paper session** **Room A**
Title: Proffered Paper session 1
Moderation: Solange Peters, CH; Alessandra Curioni, CH

09:00 - 09:00 **DOI session**

09:00 - 09:15 **LBA3 - Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 Part 2 final analysis**

L. Paz-Ares¹, T. Ciuleanu², X. Yu³, P. Salman⁴, A. Pluzanski⁵, A. Nagrial⁶, L. Havel⁷, R. Kowalyszyn⁸, C. Audigier-Valette⁹, Y.-L. Wu¹⁰, H. Borghaei¹¹, M. Hellmann¹², J. Brahmer¹³, M. Reck¹⁴, S. Ramalingam¹⁵, L. Zhang¹⁶, P. Bhagavatheeswaran¹⁷, F. Nathan¹⁷, K. O'Byrne¹⁸, ¹University Hospital 12 De Octubre and Universidad Complutense & CiberOnc, Madrid, ES, ²Prof. Dr. Ion Chiricuta Institute of Oncology and UMF Iuliu Hatieganu, Cluj- napoca, RO, ³Zhejiang Cancer Hospital, Zhejiang, CN, ⁴Fundacion Arturo Lopez Perez, Santiago, CL, ⁵Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, PL, ⁶Blacktown Hospital and University of Sydney, Sydney, AU, ⁷1st Faculty of Medicine, Charles University, Thomayer Hospital, Prague, CZ, ⁸Clinica Viedma S.A., Rio Negro, AR, ⁹Hôpital Sainte-Musse, Toulon, FR, ¹⁰Guangdong General Hospital, Guangzhou, CN, ¹¹Fox Chase Cancer Center, Philadelphia, US, ¹²Memorial

Sloan-Kettering Cancer Center, New York, US, ¹³Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, US, ¹⁴Lung Clinic Grosshansdorf, German Center for Lung Research, Grosshansdorf, DE, ¹⁵Winship Cancer Institute, Emory University, Atlanta, US, ¹⁶Sun Yat-Sen University Cancer Center, Guangzhou, CN, ¹⁷Bristol-Myers Squibb, Princeton, US, ¹⁸Princess Alexandra Hospital, Woolloongabba, AU

09:15 - 09:30 **Invited Discussant LBA3**

A. Curioni, University Hospital Zürich, Zurich, CH

09:30 - 09:45 **LBA1 - Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study**

R.S. Herbst¹, F. De Marinis², G. Giaccone³, N. Reinmuth⁴, A. Vergnenegre⁵, C. Barrios⁶, M. Morise⁷, E. Felip⁸, Z. Andric⁹, S. Geater¹⁰, M. Ozguroglu¹¹, S. Mocci¹², M. McClelland¹², W. Zou¹², I. Enquist¹², K. Komatsubara¹², Y. Deng¹², H. Kuriki¹², D. Spigel¹³, J. Jassem¹⁴, ¹Yale University School of Medicine, New Haven, US, ²Istituto Europeo di Oncologia, Milan, IT, ³Weill Cornell Medical Center, New York, US, ⁴Asklepios Lung Clinic, Munich-Gauting, DE, ⁵Centro de Pesquisa Clínica, Porto Alegre, BR, ⁶PUCRS-Pontifícia Universidade do Rio Grande do Sul, Porto Alegre, BR, ⁷Nagoya University Graduate School of Medicine, Nagoya, JP, ⁸Vall d'Hebron University Hospital, Barcelona, ES, ⁹Clinical Hospital Center Bezanijaska Kosa, Belgrade, RS, ¹⁰Prince of Songkla University, Hat Yai, TH, ¹¹University Of Istanbul Cerrahpasa Medical Faculty, Istanbul, TR, ¹²Genentech, Inc, South San Francisco, US, ¹³Sarah Cannon Research Institute, Nashville, US, ¹⁴Medical University of Gdansk, Gdansk, PL

09:45 - 10:00 **LBA4 - Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced nonsquamous NSCLC in KEYNOTE-042**

R.S. Herbst¹, G. Lopes², D. Kowalski³, K. Kasahara⁴, Y.-L. Wu⁵, G. De Castro Jr.⁶, B.C. Cho⁷, H. Turna⁸, R. Cristescu⁹, D. Aurora-Garg¹⁰, J. Luceford¹¹, J. Kobie¹¹, M. Ayers¹², M.C. Pietanza¹³, B. Piperdi¹³, T.S.K. Mok¹⁴, ¹Yale University School of Medicine, New Haven, US, ²University of Miami Sylvester Comprehensive Cancer Center, Miami, US, ³Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ⁴Kanazawa University, Kanazawa, JP, ⁵Guangdong General Hospital, Guangzhou, CN, ⁶ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, ⁷Yonsei University, Seoul, KR, ⁸Istanbul University - Cerrahpasa Medical Faculty, Istanbul, TR, ⁹MSD-Merck Sharp & Dohme, Kenilworth, US, ¹⁰MSD, Kenilworth, New Jersey, US, ¹¹Merck & Co., Inc., Kenilworth, US, ¹²MSD - Merck & Co. Inc, West Point, US, ¹³Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ¹⁴Prince of Wales Hospital, Shatin, HK

10:00 - 10:15 **Invited Discussant LBA1 and LBA4**

S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

**10:15 - 10:45 Type: Coffee break
Title: Coffee break**

Foyer ABC

10:45 - 12:15 **Type: Educational session** **Room A**
Title: Tumour microenvironment and immune cells
Moderation: Stefani Spranger, US; Johanna Joyce, CH

10:45 - 10:45 **DOI session**

10:45 - 11:05 **Immunomodulation in embryogenesis and cancer**
J. Seoane, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

11:05 - 11:25 **Targeting macrophages in glioma**
L. Akkari, The Netherlands Cancer Institute, Amsterdam, NL

11:25 - 11:45 **Impact of tumor-resident dendritic cells on anti-tumor T-cell responses**
S. Spranger, Koch Institute For Integrative Cancer Research at MIT, Cambridge, US

11:45 - 12:05 **The role of tumour-conditioned myeloid cells in shaping anti-tumor immunity**
V. Bronte, Ospedale Universitario Verona, Verona, IT

12:05 - 12:15 **General discussion / Q&A**

10:45 - 11:45 **Type: Mini Oral session** **Room C**
Title: Mini Oral session 1
Moderation: Ignacio Melero, ES; John Haanen, NL

10:45 - 10:45 **DOI session**

10:45 - 10:50 **LBA2 - First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: safety, pharmacokinetics (PK) and immunogenicity in CASPIAN**
M. Özgüroğlu¹, J. Goldman², N. Reinmuth³, Y. Chen⁴, M. Dvorkin⁵, D. Trukhin⁶, G. Statsenko⁷, K. Hotta⁸, J.H. Ji⁹, M. Hochmair¹⁰, O. Voitko¹¹, L. Havel¹², A. Poltoratskiy¹³, G. Losonczy¹⁴, F. Verderame¹⁵, M. Thomas¹⁶, Y. Zheng¹⁷, A. Lloyd¹⁸, H. Jiang¹⁶, L. Paz-Ares¹⁹, ¹Istanbul University–Cerrahpaşa, Istanbul, TR, ²David Geffen School of Medicine at UCLA, Los Angeles, US, ³Asklepios-Fachklinikum, Gauting, DE, ⁴Cancer & Hematology Centers of Western Michigan, Grand Rapids, US, ⁵BHI of Omsk Region Clinical Oncology Dispensary, Omsk, RU, ⁶Odessa Regional Cancer Center, Odessa, UA, ⁷OMSK Regional Oncology Center, Omsk, RU, ⁸Okayama University Hospital, Okayama, JP, ⁹Samsung Changwon Hospital, Changwon, KR, ¹⁰Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Krankenhaus Nord, Vienna, AT, ¹¹Kyiv City Clinical Oncological Centre, Kiev, UA, ¹²1st Faculty of Medicine, Charles University, Thomayer Hospital, Prague, CZ, ¹³Petrov Research Institute of Oncology, St Petersburg, RU, ¹⁴Semmelweis University I. Faculty of Medicine, Budapest, HU, ¹⁵Presidio Ospedaliero Cervello, Palermo, IT, ¹⁶AstraZeneca, Gaithersburg, US, ¹⁷AstraZeneca, Mountain View, US, ¹⁸AstraZeneca, Alderley Park, GB, ¹⁹University Hospital 12 De Octubre, Madrid, ES

- 10:50 - 10:55 **LBA5 - KRAS mutational status and efficacy in KEYNOTE-189: pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC**
- S. Gadgeel¹, D. Rodriguez-Abreu², E. Felip³, E. Esteban⁴, G. Speranza⁵, M. Reck⁶, R. Hui⁷, M. Boyer⁸, E. Garon⁹, H. Horinouchi¹⁰, R. Cristescu¹¹, D. Aurora-Garg¹², J. Lunceford¹³, J. Kobie¹³, M. Ayers¹⁴, B. Piperdi¹⁵, M.C. Pietanza¹⁵, M. Garassino¹⁶,
¹University of Michigan, Ann Arbor, US, ²Hospital Universitario Insular de Gran Canaria, Gran Canaria, ES, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Hospital Universitario Central de Asturias, Oviedo, ES, ⁵Centre intégré de cancérologie de la Montérégie, Université de Sherbrooke, Greenfield Park, CA, ⁶Krankenhaus Grosshansdorf, Grosshansdorf, DE, ⁷The Crown Princess Mary Cancer Centre, Westmead, AU, ⁸Chris O'Brien Lifehouse, Camperdown, AU, ⁹UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ¹⁰National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP, ¹¹MSD-Merck Sharp & Dohme, Kenilworth, US, ¹²MSD, Kenilworth, New Jersey, US, ¹³Merck & Co., Inc., Kenilworth, US, ¹⁴MSD - Merck & Co. Inc, West Point, US, ¹⁵Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ¹⁶Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
- 10:55 - 11:00 **350 - Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer**
- Y. Lin¹, S. Chen², S. Zhong², H. An³, H. Yin³, E. MCGowan¹, ¹University of Technology Sydney, Sydney, AU, ²The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, CN, ³Guangzhou Anjie Biomedical Technology Co. Ltd, Guangzhou, CN
- 11:00 - 11:05 **460 - Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated**
- A. De Giglio¹, L. Mezquita², E. Auclin³, F. Blanc-Durand², L. El-Amarti², C. Caramella², G. Martinez Bernal², L. Hendriks⁴, R. Ferrara⁵, C. Naltet², P. Lavaud², A. Gazzah², J. Adam², D. Planchard², N. Chaput⁶, B. Besse², ¹Ospedale S. Maria della Misericordia, Perugia, IT, ²Institut Gustave Roussy, Villejuif, FR, ³Hopital European George Pompidou, Paris, FR, ⁴Maastricht University Medical Center (MUMC), Maastricht, NL, ⁵Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁶Gustave Roussy Institut de Cancérologie, Villejuif, FR
- 11:05 - 11:10 **920 - Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817**
- F. Barlesi¹, C. Audigier-Valette², E. Felip³, T.-E. Ciuleanu⁴, K. Jao⁵, E. Rijavec⁶, L. Urban⁷, J.-S. Aucoin⁸, C. Zannori⁹, K. Vermaelen¹⁰, O. Arén Frontera¹¹, N. Ready¹², A. Curioni¹³, H. Linardou¹⁴, E. Poddubskaya¹⁵, J. Fischer¹⁶, R. Pillai¹⁷, S. Li¹⁸, A. Acevedo¹⁸, L. Paz-Ares¹⁹, ¹Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ²Hôpital Sainte-Musse, Toulon, FR, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴The Oncology Institute Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, RO, ⁵Hôpital du Sacré-Cœur de Montréal, Montreal, CA, ⁶Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genova, IT, ⁷Matrahaza University and Teaching Hospital, Matrahaza, HU, ⁸Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie-et-du-Centre-du-Québec, Trois-Rivières, CA, ⁹Azienda Ospedaliera Santa Maria di Terni, Terni,

IT, ¹⁰Ghent University Hospital, Ghent, BE, ¹¹Centro Internacional de Estudios Clinicos, Santiago, CL, ¹²Duke Cancer Center, Durham, US, ¹³University Hospital Zürich, Zurich, CH, ¹⁴Metropolitan Hospital, Athens, GR, ¹⁵VitaMed LLC, Moscow, RU, ¹⁶Löwenstein Clinic gGmbH, Löwenstein, DE, ¹⁷Winship Cancer Institute, Emory University, Atlanta, US, ¹⁸Bristol-Myers Squibb, Princeton, US, ¹⁹Hospital Universitario 12 de Octubre, Madrid, ES

11:10 - 11:15

470 - Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice

A. Drakaki¹, P. Luhn², H. Wakelee³, P. Dhillon², M. Kent⁴, J. Shim⁵, V. Degaonkar², T. Hoang², V. McNally⁶, S. Chui², R. Gutzmer⁷, ¹Ronald Reagan UCLA Medical Center, Los Angeles, US, ²Genentech, Inc., South San Francisco, US, ³Stanford Medical School, Stanford, US, ⁴Genesis Research, Hoboken, US, ⁵F. Hoffmann-La Roche, Ltd., Basel, CH, ⁶F. Hoffmann-La Roche, Ltd., Welwyn Garden City, GB, ⁷Hannover Medical School, Hanover, DE

11:15 - 11:20

930 - First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers

M. Johnson¹, A. Spira², D. Carbone³, C. Drake⁴, B. Henick⁴, M. Ingham⁵, K. Caldwell⁶, S. Chan⁶, M. Hart⁶, A. Malloy⁶, E. Maloney⁶, C. Palmer⁶, A. Yang⁶, M. Zhong⁶, P. Basciano⁷, E. Bournazou⁷, A. Ferguson⁶, D. Catenacci⁸, ¹Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ²Virginia Cancer Specialist, Fairfax, US, ³Ohio State University Medical Center, Columbus, US, ⁴Columbia University Medical Center/New York Presbyterian Hospital, New York, US, ⁵Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ⁶Gritstone Oncology, Emeryville, US, ⁷Bristol-Meyers Squibb, Lawrenceville, US, ⁸The University of Chicago Medical Centre, Chicago, US

11:20 - 11:45

Discussion led by Moderators

I. Melero¹, J. Haanen², ¹Clinica Universitaria de Navarra, Pamplona, ES, ²Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

12:15 - 13:15

**Type: Poster Display session
Title: Lunch & Poster Display session**

Room B

12:15 - 12:15

5P - Differential expression patterns of immune checkpoint markers in tumour-stromal microenvironment of primary and chemoreduced retinoblastoma

L. Singh¹, M. Singh², M. Rizvi³, N. Pushker⁴, S. Sen², S. Kashyap⁵, ¹AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ²All India Institute of Medical Sciences, Delhi, IN, ³Jamia Millia Islamia, New Delhi, IN, ⁴All India Institute of Medical Sciences, New delhi, IN, ⁵All India Institute of Medical Sciences, New Delhi, IN

12:15 - 12:15

6P - Prognostic significance of tumour-infiltrating lymphocytes on survival outcomes of patients with resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis

H.N. Tan, L.I. Catedral, M. San Juan, University of the Philippines - Philippine General

Hospital, Manila, PH

- 12:15 - 12:15 **7P - Multispectral immunofluorescence and computational imaging analysis define the prognostic role of T-cell infiltrates in gastric cancer**
B. Challoner¹, K. Von Loga², A. Woolston¹, B. Griffiths¹, L. Hewitt³, Y. Saito⁴, N. Sivamanoharan², D. Mansfield¹, A. Melcher⁵, H. Grabsch³, M. Gerlinger⁶, ¹ICR - Institute of Cancer Research, London, GB, ²Royal Marsden Hospital, London, GB, ³Maastricht University, Maastricht, NL, ⁴Cancer Institute Hospital of JFCR, Tokyo, JP, ⁵The Institute of Cancer Research, London, London, GB, ⁶The Institute of Cancer Research (ICR), London, GB
- 12:15 - 12:15 **8P - The prognostic value of tumour-infiltrating lymphocytes (TILs) in pancreatic cancer: A systematic review and meta-analysis**
A. Orhan¹, R. Vogelsang², M. Andersen², M. Madsen², E. Hölmich², H. Raskov², I. Gögenur², ¹Copenhagen University, Copenhagen, DK, ²Center for Surgical Science, Koege, DK
- 12:15 - 12:15 **9P - Overall assessment of tumour-infiltrating lymphocytes in early-stage nasopharyngeal carcinoma**
A. Almangush, University of Helsinki - Haartman Institute, Helsinki, FI
- 12:15 - 12:15 **10P - Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC**
G. Mazzaschi¹, R. Minari¹, V. Ferri², L. Gnetti³, M. Bersanelli⁴, A. Cavazzoni², P. Bordi⁵, A. Squadrilli¹, S. Buti⁵, A. Cosenza¹, L. Ferri¹, E. Rapacchi¹, P.G. Petronini⁵, G. Missale¹, F. Quaini⁵, M. Tiseo⁵, ¹University Hospital of Parma, Parma, IT, ²University of Parma, Parma, IT, ³Azienda Ospedaliera di Parma, Parma, IT, ⁴Azienda Ospedaliero-Universitaria di Parma, Parma, IT, ⁵AOU di Parma, Parma, IT
- 12:15 - 12:15 **11P - PD-L1 profiling of circulating tumour cells is a viable companion diagnostic for checkpoint inhibitor therapy in lung cancer**
R. Patil¹, S. Limaye², D. Akolkar¹, D. Patil¹, V. Datta¹, P. Devhare¹, S. Patel¹, A. Srinivasan¹, R. Datar¹, ¹Datar Cancer Genetics, Nashik, IN, ²Kokilaben Dhirubhai Ambani Hospital, Mumbai, IN
- 12:15 - 12:15 **12P - The expression of PD-1 alone by T cells is associated with cell activation while the co-expression of TIM-3 indicates exhausted subsets both in peripheral blood and bone marrow of multiple myeloma patients**
E. Batorov¹, V. Sergeevicheva², T. Aristova², S. Sizikova², G. Ushakova², A. Maximova², A. Morenkova², E. Shevela², A. Ostanin², E. Chernykh², ¹Scientific Research Institute of Clinical Immunology (ICI), Novosibirsk, RU, ²Research Institute of Fundamental and Clinical Immunology, Novosibirsk, RU
- 12:15 - 12:15 **13P - MDSC (myeloid-derived suppressor cells) is an important immunosuppressing factor and functionally related with VEGF and IL-17 in patients with gastrointestinal cancer**
M. Shibata¹, T. Nakajima², K. Mimura², T. Shimura², K. Kono², S. Takenoshita², ¹Saitama

Medical University Internatl Medical Centre, Saitama, JP, ²Fukushima Medical University, Fukushima, JP

- 12:15 - 12:15 **14P - Anti-PDL1/IL-15 fusion protein increases rare effector cells in cynomolgus monkeys and mice**
S. Martomo¹, D. Lu², Z. Polonskaya³, X. Luna³, F. Miyara³, J. Patel³, ¹Kadmon Corporation - Kadmon Holdings, Inc., New York City, US, ²Kadmon Corporation - Kadmon Holdings, Inc., Edgewater, US, ³Kadmon Corporation - Kadmon Holdings, Inc., New York, US
- 12:15 - 12:15 **15P - Immune escape in acute myeloid leukemia**
K. Kuzelova, B. Brodská, P. Otevřelová, C. Šálek, Z. Gašová, M. Petráčková, Institute of Hematology and Blood Transfusion, Prague, CZ
- 12:15 - 12:15 **16P - Neutrophil-lymphocyte ratio as a prognostic marker in a resource constraint setting for metastatic malignancies treated with immune checkpoint inhibitors**
N. Murthy, A. Rauthan, P. Patil, S. Somashekhar, S. Zaveri, K. Lahkar, K. Gupta, G. Nigade, T. Sood, S. Kulkarni, Manipal Comprehensive Cancer Center Manipal Hospital, Bangalore, IN
- 12:15 - 12:15 **17P - Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients**
F. Blanc-Durand¹, E. Auclin², D. Planchard³, S. Ponce Aix⁴, L. Hendriks⁵, I.G. Sullivan⁶, D. Saravia⁷, B. Routy⁸, R. Lopez Castro⁹, S. Pilotto¹⁰, F. Aboubakar¹¹, E. Kassouf¹², A. Rodriguez¹³, A. Amores Martin¹⁴, M. Bluthgen¹⁵, B. Duchemann¹⁶, C. Caramella³, E. Nadal¹⁷, B. Besse³, L. Mezquita³, ¹Institut Curie, Paris, FR, ²Hopital European George Pompidou, Paris, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴University Hospital 12 De Octubre, Madrid, ES, ⁵Maastricht University Medical Center (MUMC), Maastricht, NL, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁷Jackson Memorial Hospital, Miami, US, ⁸University of Montreal Research Center, Montreal, CA, ⁹University Clinical Hospital of Valladolid, Valladolid, ES, ¹⁰AOU Integrata Borgo Roma Verona, Verona, IT, ¹¹UCLouvain Brussels Woluwe, Brussels, BE, ¹²Centre Hospitalier Régional de Lanaudière, St-Charles-Borromée, CA, ¹³Institut Clínic de Malalties Hematològiques i Oncològiques, Barcelona, ES, ¹⁴Hospital Clinico Universitario de Salamanca, Salamanca, ES, ¹⁵Hospital Aleman, Buenos Aires, AR, ¹⁶Hôpital Avicenne, Bobigny, FR, ¹⁷Institut Catala d'Oncologia (ICO), Barcelona, ES
- 12:15 - 12:15 **18P - The role of circulating neutrophils in the regulation of neoangiogenesis in ovarian cancer**
T. Abakumova¹, I. Antoneeva², S. Gening¹, D. Dolgova¹, T. Gening¹, ¹Ulyanovsk State University, Ulyanovsk, RU, ²Regional Clinical Oncology Center, Ulyanovsk, RU
- 12:15 - 12:15 **19P - The prognostic nutritional index and neutrophil-to-lymphocyte ratio as prognostic factors in advanced non-small cell lung cancer patients treated with immunotherapy**
É. Cipriano¹, H. Magalhães², F. Estevinho², C. Sottomayor², ¹Hospital Pedro Hispano,

Matosinhos, PT, ²Hospital Pedro Hispano, Matosinhos Local Health Unit, Matosinhos, PT

- 12:15 - 12:15 **20P - The immune profiles in young, adult and elderly of advanced stage colorectal cancer patients**
I.B. Budhi¹, M. Ida Bagus¹, S. Ida Ayu², I. Darmawan¹, S. Widyanti¹, Y.Y. Kristanto¹,
¹Sebelas Maret University, Surakarta, ID, ²Pendidikan Ganesha University, Singaraja Bali, ID
- 12:15 - 12:15 **21P - Prognostic biomarkers in lung cancer patients treated with immunotherapy**
S. Ferreira¹, S. Esteves², M.T. Almodovar¹, ¹Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT, ²Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, PT
- 12:15 - 12:15 **22P - Early changes in plasma cell-free DNA (cfDNA) as a predictive biomarker of immune checkpoint inhibitors (ICIs) efficacy**
I. Matos Garcia¹, A. Moreno², C. Arenillas¹, C. Hierro Carbo³, E. Munoz-Cosuelo², J. Martin-Liberal⁴, I. Braña⁵, M. Vieito Villar⁵, A. Azaro⁶, O. Saavedra Santa Gadea⁵, I. Gardeazabal Gonzalez⁵, R. Javier², B. Roger², E. Elez², E. Felip⁷, R. Dienstmann⁵, A. Gros⁸, J. Tabernero⁹, R. Toledo¹, E. Garralda⁸, ¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ²Vall d'Hebron Institute of Oncology, Barcelona, ES, ³ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ⁴Vall d'Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ⁵Vall d'Hebron University Hospital, Barcelona, ES, ⁶NO institution, NO City, CH, ⁷Vall d'Hebron University Hospital, Barcelona, ES, ⁸Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁹Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES
- 12:15 - 12:15 **23P - Immunological signature meta-analysis across lung cancer cohorts within the NanoString Clinical Transcriptional Atlas Group (CTAG) associated with patient outcome and history**
N. Radosevic-Robin¹, J. Reeves², K. Leroy³, M. Duruisseaux⁴, P. Morel², M. Bhagat⁵, F. Penault-Llorca¹, D. Damotte⁶, F. Goldwasser³, A. Brindel⁷, M. Cumberbatch⁵, S. Ong², J. Lopez⁸, S. Warren², ¹Centre Jean Perrin, Clermont-Ferrand, FR, ²NanoString Technologies, Seattle, US, ³University Paris Descartes APHP, Hospital Cochin, Paris, FR, ⁴Hôpital Louis Pradel-Hospices Civils de Lyon, Bron, FR, ⁵TriStar Technology Group, Washington DC, US, ⁶Université Paris Descartes, Paris, FR, ⁷Groupement Hospitalier Est, Bron, FR, ⁸Hospices Civiles de Lyon, Lyon, FR
- 12:15 - 12:15 **24P - Multiple KRAS mutations detected by cancer related DNA in patients with resected pancreas adenocarcinoma during treatment with TG01/GM-CSF and gemcitabine (CT TG01-01)**
D. Palmer¹, A.-S. Møller², B. Greenhalf³, Y. Ma⁴, J. Valle⁵, T. Gjertsen², L. Kuryk⁶,
¹University of liverpool cancer research UK center, liverpool, GB, ²Targovax, Oslo, NO, ³University of Liverpool, Liverpool, GB, ⁴Queen Elizabeth University Hospital, Birmingham, GB, ⁵University of Manchester, Manchester, GB, ⁶Targovax, Oslo, FI
- 12:15 - 12:15 **25P - Analysis of NGS-based blood immune cell RNA signatures for colorectal**

cancer detection

S. Morgenthaler¹, H. Lindsay¹, L. Ciarloni², P. Angelino³, G. Dorta⁴, M. Delorenzi⁵, S. Hosseinian Ehrensberger², ¹Ecole Polytechnique Fédérale de Lausanne, Lausanne, CH, ²Novigenix, Epalinges, CH, ³SIB Swiss Institute of Bioinformatics, Lausanne, CH, ⁴CHUV, Lausanne, CH, ⁵Swiss Institute of Bioinformatics, Lausanne, CH

12:15 - 12:15 **26P - Transforming growth factor-&&**

S. Zaitsev¹, V. Shevchenko², N. Arnotskaya², I. Lyakhova¹, Y. Khotimchenko¹, I. Bryukhovetskiy¹, ¹Far Eastern Federal University, Vladivostok, RU, ²Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU

12:15 - 12:15 **27P - Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI)**

F. Costa Svedman¹, M. Yang², R. Tuominen², S. Brage², V. Höiom², ¹Karolinska University Hospital-Solna, Solna, SE, ²Karolinska Institute, Stockholm, SE

12:15 - 12:15 **28P - RNA-seq based transcriptome profiling provides important insights into progression of gastric cancer**

R. Verma, Guru Gobind Singh Indraprastha University, Delhi, IN

12:15 - 12:15 **29P - Expression profiles of serum long non-coding RNA in ovarian cancer patients receiving platinum-containing chemotherapy**

S. Gening¹, D. Dolgova¹, T. Abakumova¹, A. Rizvanov², I. Antoneeva³, ¹Ulyanovsk State University, Ulyanovsk, RU, ²Kazan Federal University, Kazan, RU, ³Regional Clinical Oncology Center, Ulyanovsk, RU

12:15 - 12:15 **30P - Transcriptomic landscape of tumour cells undergoing T-cell attack**

A. Gokuldass¹, A. Schina¹, M. Lauss², K. Harbst², C.A. Chamberlain³, A. Draghi⁴, M. Westergaard³, M. Nielsen³, K. Papp⁵, Z. Sztupinski⁶, I. Casabi⁷, I.M. Svane¹, Z. Szallasi⁶, G. Jönsson², M. Donia⁴, ¹Herlev Hospital, Herlev, DK, ²Lund University, Lund, SE, ³Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK, ⁴Herlev Hospital - National Center for Cancer Immune Therapy, Herlev, DK, ⁵Eotvos lorand University, Budapest, HU, ⁶Danish Cancer Socieity, Copenhagen, DK, ⁷ELTELTE Eötvös Loránd University, Budapest, HU

12:15 - 12:15 **31P - Development of a biomarker-based calculator to predict the probability to achieve a pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer**

L. Marandino¹, M. Bandini², R. Madison³, D. Raggi⁴, A. Gallina², M. Colecchia⁵, R. Lucianò², P. Giannatempo⁴, E. Farè⁴, F. Pederzoli², M. Bianchi², R. Colombo², U. Capitanio², S.M. Ali³, J.H. Chung³, J. Ross³, A. Salonia², A. Briganti², F. Montorsi⁶, A. Necchi⁴, ¹Istituto di Candiolo - FPO - IRCCS, Candiolo, IT, ²Vita Salute San Raffaele University and Urological Research Institute, Milan, IT, ³Foundation Medicine, Inc, Cambridge, US, ⁴Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁶IRCCS Ospedale San

Raffaele, Milan, IT

- 12:15 - 12:15 **32P - A comprehensive tumour immunogenomics platform for precision immunotherapy: Enabling simultaneous characterization of tumours and the TME from a single FFPE sample**
R. Power, G. Bartha, J. Harris, S. Boyle, E. Levy, P. Milani, P. Tandon, R. Li, M. Chinnappa, A. Haddad, P. Mcnitt, R. McClory, M. Morra, S. Saldivar, M. Clark, C. Haudenschild, E. Newburn, C. Johnson, R. Chen, J. West, Personalis, Inc., Menlo Park, US
- 12:15 - 12:15 **33P - Tumour mutational burden ring trial: Evaluation of targeted next-generation sequencing platforms for implementation in clinical practice**
S. Lambin¹, D. Lambrechts², C. De Rop³, N. D'Haene⁴, G. Froyen⁵, L. Heukamp⁶, C. Huijsmans⁷, B. Maes⁵, B. Melendez⁴, C. Van Campenhout⁴, I. Vanden Bempt⁸, A. Van Den Brule⁷, S. Vander Borght⁸, P. Vannuffel³, P. Pauwels¹, ¹University Hospital Antwerp (UZA), Edegem, BE, ²VIB-KU Leuven Center for Cancer Biology, Leuven, BE, ³Institut de Pathologie et de Génétique, Gosselies, BE, ⁴Erasmus hospital, Université libre de Bruxelles, Brussels, BE, ⁵Jessa Hospital, Hasselt, BE, ⁶Institute For Hematopathology, Hamburg, DE, ⁷Jeroen Bosch Hospital, s-Hertogenbosch, NL, ⁸University of Leuven, Leuven, BE
- 12:15 - 12:15 **34P - Development of LAG-3 nanobodies as potent cancer imaging tracers**
Q. Lecocq¹, R. Awad², K. Zeven², Y. De Vlaeminck², W. De Mey², P. Debie², J. Puttemans², C. Goyvaerts², G. Raes², M. Keyaerts³, N. Devoogdt², K. Breckpot², ¹Vrije Universiteit Brussel-Campus Jette, Brussels, BE, ²VUB, Jette, BE, ³UZ Brussels, Jette, BE
- 12:15 - 12:15 **36P - First CAR-T cell immunotherapy against HLA-G: Targeting a unique ICP and TAA**
M. Loustau, Invectys SA, Paris, FR
- 12:15 - 12:15 **37P - Chemokine receptor CCR2b expressing anti-Tn-MUC1 CAR-T cells enhanced anti-breast cancer activity**
Y. Lin¹, H. Yin², H. An², C. Zhou², L. Zhou², S. Chen³, E. McGowan⁴, ¹University of Technology Sydney, Sydney, AU, ²Guangzhou Anjie Biomedical Technology Co. Ltd, Guangzhou, CN, ³The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, CN, ⁴First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, CN
- 12:15 - 12:15 **38P - Obtaining tumour-specific T cells in a mouse melanoma model**
D. Yuzhakova¹, A. Izosimova¹, L. Barbashova², E. Zagaynova¹, G. Sharonov¹, D. Chudakov³, ¹Privolzhsky Research Medical University, Nizhny Novgorod, RU, ²Privolzhsky Research Medical University, Nizhny Novgorod, BL, ³Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, RU
- 12:15 - 12:15 **39P - TCR engaging antigen-scaffolds for targeted expansion of functionally improved T cells for adoptive cell therapy**
G. Kladis¹, V. Rafa Mindahl², T. Tamhane³, A. Kai Bentzen³, M. Donia⁴, I.M. Svane⁵, H. Niessner⁶, T. Sinnberg⁶, C. Garbe⁷, S. Nyboe Jacobsen⁸, C. Schmees⁹, S. Reker Hadrup¹⁰, ¹Technical University of Denmark, Kongens Lyngby, DK, ²Technical University

of Denmark, Copenhagen, DK, ³Technical University of Denmark, Kgs Lyngby, DK, ⁴Herlev Hospital - National Center for Cancer Immune Therapy, Herlev, DK, ⁵Herlev Hospital, Herlev, DK, ⁶Universitätsklinikum Tübingen, Tübingen, DE, ⁷Universitaets-Hautklinik Tuebingen, Tuebingen, DE, ⁸Technical University of Denmark, Kgs Lygby, DK, ⁹Universitätsklinikum Tübingen, Tuebingen, DE, ¹⁰National Veterinary Institute (DTU Vet), Copenhagen, DK

- 12:15 - 12:15 **40P - Treatment of refractory recurrent gastrointestinal stromal tumors with adoptive cellular immunotherapy (TILs) and personalized vaccine**
A. Tavartkiladze¹, R. Khutsishvili², P. Revazishvili², M. Maisuradze², L. Tavartkiladze², G. Tavartkiladze², ¹Institute For Personalized Medicine, Tbilisi, GE, ²Institute for Personalized Medicine, Tbilisi, GE
- 12:15 - 12:15 **41P - Pharmacotherapy preceding monocyte harvest interferes with the potency of monocyte-derived dendritic cell anticancer vaccine**
E. Hlavackova¹, K. Pilatova², L. Fedorova², P. Mudry³, P. Mazanek⁴, J. Sterba¹, L. Zdrzilova Dubska², ¹University Hospital Brno-Children's Medical Centre, Brno, CZ, ²Masaryk Memorial Cancer Institute, Brno, CZ, ³Masaryk University Faculty of Medicine, Brno, CZ, ⁴University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, CZ
- 12:15 - 12:15 **42P - GMP-compliant human monocyte-derived dendritic cells for cancer vaccination generated by using the Quantum® hollow fiber bioreactor system**
U. Uslu¹, M. Erdmann², M. Wiesinger², G. Schuler², B. Schuler-Thurner¹, ¹Universitätsklinik Erlangen, Erlangen, DE, ²Universitätsklinikum Erlangen, Erlangen, DE
- 12:15 - 12:15 **43P - Enhancing the therapeutic effect of dendritic cell therapy by oncolytic adenovirus 3 encoding CD40-ligand**
S. Zafar¹, D. Quixabeira¹, O. Hemminki¹, V. Cervera-Carrascon², J.M. Santos¹, A. Kanerva¹, A. Hemminki³, ¹University of Helsinki, Helsinki, FI, ²University of Helsinki-Faculty of medicine, Helsinki, FI, ³University of Helsinki and TILT Biotherapeutics, Helsinki, FI
- 12:15 - 12:15 **44P - Evaluation of immune response in young patients with sarcoma treated by dendritic cell-based immunotherapy**
L. Fedorova¹, L. Zdrzilova Dubska¹, I. Selingerova¹, K. Pilatova¹, P. Mudry², J. Sterba³, R. Demlova¹, D. Valik⁴, ¹Masaryk Memorial Cancer Institute, Brno, CZ, ²Masaryk University Faculty of Medicine, Brno, CZ, ³University Hospital Brno-Children's Medical Centre, Brno, CZ, ⁴Masaryk University, Faculty of Medicine, Brno, CZ
- 12:15 - 12:15 **45P - 5-AZA treatment induces cytotoxicity and in vitro expression of immunogenic NY-ESO-1 antigen in non-small lung cancer cell NCI-H1975**
V. Inchakalody¹, S. Taleb², S. Sherif², Q. Fernandes², F. Sahir³, S.K. Sivaraman³, A. Khan³, V. Sasidharan Nair⁴, E. Ashi A.A⁴, L. Al-Zaidan², A. Iskandarani³, R. Krishnankutty³, L. Therachiyil³, A. Raza², M. Merhi², S. Uddin³, E. Elkord⁴, S. Dermime², ¹Hamad Medical Corporation (HMC) - National Center for Cancer Care and Research (Al

Amal Hospital), Ad-Dawhah, QA, ²Hamad Medical Corporation (HMC)-National Center for Cancer Care and Research (Al Amal Hospital), Doha, QA, ³Hamad Medical Corporation (HMC), Doha, QA, ⁴Qatar Biomedical Research Institute, Doha, QA

- 12:15 - 12:15 **48P - A retrospective, observational study of telomerase peptide immunotherapy in heavily treated solid cancer patients**
J.G. Choi, konyang university hospital, Daejeon, KR
- 12:15 - 12:15 **49P - Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study**
P. Bravo¹, B. Vss¹, C. Baldini², P. Martin Romano², A. Hollebecque³, A. Varga³, P. Vuagnat³, S. Champiat², A. Marabelle³, B. Escudier¹, L. Albiges³, Y. Loriot³, C. Massard⁴, A. Cataldi², S. Babai², A.-L. Voisin², O. Lambotte⁵, M. Annereau², J.-M. Michot³, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Gustave Roussy, Villejuif, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴Institut Gustave Roussy, Paris, FR, ⁵CHU de Bicêtre, Le Kremlin Bicetre, FR
- 12:15 - 12:15 **50P - Predicting onset and continuity of patient-reported symptoms in cancer patients undergoing immune checkpoint inhibitor (ICI) therapies using machine learning**
S. Iivanainen¹, J. Ekström², H. Virtanen², J. Koivunen¹, ¹Oulu University Hospital, Oulu, FI, ²Kaiku Health Oy, Helsinki, FI
- 12:15 - 12:15 **51P - Oncologists' consideration of health-related quality of life in clinical practice for immune-checkpoint inhibitors-treated patients: An online patients community research**
O. Wilczynski¹, A. Boisbouvier¹, L. Radoszycki¹, F.-E. Cotté², A.-F. Gaudin², H. Lemasson², ¹CARENITY, Paris, FR, ²Bristol-Myers Squibb, Rueil-Malmaison, FR
- 12:15 - 12:15 **52P - Chronic and late-onset toxicities from immune checkpoints inhibitors (ICIs): Analysis of the publications leading to ICIs approval between 2011 and 2019**
E. Ghisoni¹, L. Marandino², G. Valabrega³, M. Aglietta¹, M. Di Maio⁴, ¹IRCCS Candiolo, Candiolo, IT, ²Candiolo Cancer Institute, FPO-IRCCS, Candiolo, IT, ³Istituto di Candiolo - FPO - IRCCS, Candiolo, IT, ⁴Azienda Ospedaliera Mauriziano Umberto I, IT
- 12:15 - 12:15 **53P - Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience**
N.S. Samanci¹, K. Oruc¹, S. Bedir¹, E. Celik¹, E. Degerli², S. Derin¹, F.H. Demirelli³, M. Ozguroglu¹, ¹University Of Istanbul Cerrahpasa Medical Faculty, Istanbul, TR, ²Istanbul University - Cerrahpasa Faculty of Medicine, Istanbul, TR, ³Cerrahpasa Faculty of Medicine - Istanbul University, Istanbul, TR
- 12:15 - 12:15 **54P - Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors**
P. Vuagnat¹, E. Auclin², L. Mezquita¹, J. Adeva Alfonso³, M.R. Vidal Tocino⁴, F. Longo Munoz⁵, Y. El Dakdouki¹, P. Martin Romano⁶, C. Baldini⁶, A. Varga¹, R. Garcia-

Carbonero³, B. Besse¹, C. Massard⁷, A. Hollebecque¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Hopital European George Pompidou, Paris, FR, ³University Hospital 12 De Octubre, Madrid, ES, ⁴Salamanca University Healthcare Complex, Salamanca, ES, ⁵Hospital Universitario Ramon y Cajal, Madrid, ES, ⁶Gustave Roussy, Villejuif, FR, ⁷Gustave Roussy - Cancer Campus, Villejuif, FR

12:15 - 12:15

55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study

O. Nigro¹, A. Cortellini², R. Giusti³, P. Marchetti³, F. De Galitiis⁴, F. Di Pietro⁴, M. Bersanelli⁵, A. Lazzarin⁵, D. Galetta⁶, P. Pizzutillo⁶, D. Santini⁷, M. Torniai⁸, A. De Giglio⁹, A. Russo¹⁰, R. Silva¹¹, E. Bolzacchini¹², C. Natoli¹³, E. Rijavec¹⁴, I. Vallini¹⁵, G. Pinotti¹⁶, ¹Ospedale di Circolo Fondazione Macchi, Varese, IT, ²St. Salvatore Hospital, L'Aquila, IT, ³Azienda Ospedaliero-Universitaria Sant'Andrea, Rome, IT, ⁴IDI-IRCCS, Rome, IT, ⁵Azienda Ospedaliero-Universitaria di Parma, Parma, IT, ⁶Clinical Cancer Centre Giovanni Paolo II, Bari, IT, ⁷Campus Bio-Medico, Rome, IT, ⁸Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi, Ancona, IT, ⁹Ospedale S. Maria della Misericordia, Perugia, IT, ¹⁰A.O. Papardo & Department of Human Pathology, Messina, IT, ¹¹ASUR Marche, Area Vasta 2, Fabriano, IT, ¹²ASST Lariana, Ospedale Sant'Anna, Como, IT, ¹³S.S. Annunziata Hospital, Chieti, IT, ¹⁴Ospedale Policlinico San Martino, Genova, IT, ¹⁵ASST-Sette Laghi, Ospedale di Circolorcolo, Varese, IT, ¹⁶ASST-Sette Laghi, Ospedale di Circolo, Varese, IT

12:15 - 12:15

56P - Predictive factors of intensive care outcomes of patients admitted with immune-related adverse events

R. Paiva¹, E. Cojocaru², V. Grover², ¹Centro Hospitalar de Lisboa Norte (CHLN)- Hospital Santa Maria (HSM), Lisbon, PT, ²The Royal Marsden Hospital, London, GB

12:15 - 12:15

57P - Immune-related adverse events: The experience of a community hospital

S. Baptista De Almeida¹, M. Honório², N. Guerra³, T. Fiúza², ¹Hospital Prof. Dr Fernando Fonseca E.P.E (Amadora/Sintra), Amadora, PT, ²Hospital Prof. Doutor Fernando Fonseca, Amadora, PT, ³Centro Hospitalar Barreiro Montijo, Barreiro, PT

12:15 - 12:15

58P - Risk factors for immune related adverse events: A retrospective study

A. Parmanande, J. Barreira, A. Spencer, A. Reis, M. Sardinha, D. Simão, R. Luz, Centro Hospitalar de Lisboa Central (CHLC)-Hospital de Santo António dos Capuchos (HSAC), Lisbon, PT

12:15 - 12:15

59P - Checkpoint inhibitors and conventional therapy for central nervous system lymphoma

D. Shmidt¹, A. Gavrilenko², A. Polushin², E. Kondakova³, K. Lepik³, N. Medvedeva⁴, A. Klimovich⁴, Y. Zalyalov³, N. Mikhaylova³, B. Afanasyev³, ¹Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, ²R. M. Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation; Chair of Hematology, Transfusiology and Transplantology, Pavlov First Saint Petersburg State Medical University, Saint-Petesburg, RU, ³Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Saint Petersburg, RU, ⁴State Clinical Hospital №31 of Saint-Petersburg, Saint-Petesburg, RU

- 12:15 - 12:15 **60P - (Withdrawn)**
- 12:15 - 12:15 **61P - Immunotherapy in patients with relapsed/refractory HIV-related lymphomas**
M. Popova¹, Y. Rogacheva², I. Tsygankov³, K. Lepik¹, Y. Zalyalov¹, L. Stelmakh⁴, I. Moiseev¹, S. Bondarenko¹, N. Mikhaylova¹, V. Baykov¹, B. Afanasyev¹, ¹Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Saint Petersburg, RU, ²Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, ³Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Санкт-Петербург, RU, ⁴Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation R.M. Gorbacheva, RU
- 12:15 - 12:15 **62P - Safety and efficacy of allogeneic stem cell transplantation after nivolumab therapy for patients with relapsed/refractory classical Hodgkin lymphoma**
A. Beynarovich¹, K. Lepik², N. Mikhailova³, E. Kondakova², Y. Zalyalov², I. Moiseev², B. Afanasyev², ¹Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, ²Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Saint Petersburg, RU, ³Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation R.M. Gorbacheva, RU
- 12:15 - 12:15 **63P - Influence of nivolumab on epidemiology of infectious complications in patients with relapse or refractory Hodgkin's lymphoma**
Y. Rogacheva¹, M. Popova², K. Lepik², E. Kondakova², Y. Zalyalov², L. Stelmah², A. Volkova², I. Nikolaev², O. Goloshchapov², I. Barhatov², S. Bondarenko², I. Moiseev², V. Baykov², N. Mikhailova³, N. Klimko⁴, B. Afanasyev², ¹Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, ²Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Saint Petersburg, RU, ³Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation R.M. Gorbacheva, RU, ⁴Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Санкт-Петербург, RU
- 12:15 - 12:15 **64P - Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?**
J. Lee¹, K. Ng², L. Wong², A. Ang², S.H. Tan², D. Tai², S.P. Choo², ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²National Cancer Centre Singapore, Singapore, SG
- 12:15 - 12:15 **65P - Determination of anti-pancreatic islet cell antibodies for the prevention of type 1 diabetes mellitus as an immune-related adverse event secondary to treatment with immune checkpoint inhibitors**
A. Olivares Hernández¹, R. Escala Cornejo², L. Figuero Pérez¹, M.R. Vidal Tocino¹, E. Escalera Martín¹, J. Claros Ampuero¹, A. Amores Martín³, C. Rodríguez Sánchez¹, R. Gonzalez Sarmiento⁴, J. Miramontes González⁵, J. Cruz-Hernández¹, ¹Salamanca University Healthcare Complex, Salamanca, ES, ²IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ³Hospital Clínico Universitario de Salamanca, Salamanca, ES, ⁴Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, ES, ⁵Valladolid University Healthcare Complex, Valladolid, ES

- 12:15 - 12:15 **66P - Efficacy and safety of nintedanib & docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)**
C. Grohe¹, W. Gleiber², S. Krüger³, H. Mueller-Huesmann⁴, M. Schulze⁵, J. Atz⁶, R. Kaiser⁶, ¹Evangelische Lungenklinik ELK Berlin Chest Hospital, Berlin, DE, ²University Hospital, Goethe University, Frankfurt, Germany, Frankfurt/Main, DE, ³Florence-Nightingale-Krankenhaus, Düsseldorf, DE, ⁴Brüderkrankenhaus St. Josef, Paderborn, DE, ⁵Ambulante Onkologie Ostsachsen, Zittau, DE, ⁶Boehringer Ingelheim Pharma-Germany, Ingelheim am Rhein, DE
- 12:15 - 12:15 **67P - Real-world outcomes for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab**
P. Singh¹, M. You², S. Lubinga¹, Y. Zhang¹, ¹Bristol-Myers Squibb, Princeton, US, ²Bristol-Myers Squibb, Lawrenceville, US
- 12:15 - 12:15 **68P - Dynamic changes in neutrophil-to-lymphocyte ratio of head and neck cancer patients receiving nivolumab in a real-world setting**
S. Cabezas-Camarero¹, D. Gutierrez Abad², L. Ugidos De La Varga³, J. Corral Jaime⁴, P. Pérez-Segura¹, ¹Hospital Clinico Universitario San Carlos, Madrid, ES, ²Hospital de Fuenlabrada, ES, ³Hospital de Madrid Norte-Sanchinarro, Madrid, ES, ⁴Clínica Universitaria de Navarra, Madrid, ES
- 12:15 - 12:15 **69P - Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)**
A. Hernando-Calvo¹, O. Mirallas¹, D. Marmolejo¹, E. Felip², G. Villacampa Javierre³, E. Garralda⁴, R. Gutierrez⁴, B. Feliu⁴, S. Martínez⁴, R. Dienstmann¹, I. Braña¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 12:15 - 12:15 **70P - Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors**
P. Ayala De Miguel¹, J. López Gallego², I. Gorospe García², A. Illán Varela², P.R. Rivera Vargas², A. Posada Restrepo², P. Borrega García², ¹Hospital San Pedro De Alcantara, Cáceres, ES, ²Hospital San Pedro de Alcántara, Cáceres, ES
- 12:15 - 12:15 **71P - Correlation between toxicities and outcomes during treatment with immune checkpoint inhibitors in non-small cell lung cancer patients**
P. Ayala De Miguel¹, S. Arnáiz Díez², I. Gorospe García², J. López Gallego², A. Illán Varela², P. Borrega García², ¹Hospital San Pedro De Alcantara, Cáceres, ES, ²Hospital San Pedro de Alcántara, Cáceres, ES
- 12:15 - 12:15 **72P - Evaluation of the correlation between diverticulosis and the onset of diarrhea in patients with lung cancer treated with immune checkpoint inhibitors**
G. Negrini¹, L. Ghilardi¹, L. Bonomi², E. Arnoldi², C.A. Tondini², C. Sansi², A.C. Bettini²,

¹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, ²Azienda Ospedaliera Papa Giovanni XXIII, BERGAMO, IT

- 12:15 - 12:15 **73P - Real-world experience of immune-mediated hepatitis in Danish lung cancer patient using PD1 inhibitors**
L. Lauritsen¹, G. Persson¹, M. Poehl², K. Skougaard¹, ¹Herlev Hospital, Herlev, DK, ²Rigshospitalet, Copenhagen Ø, DK
- 12:15 - 12:15 **74P - Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world**
C.K. Wang¹, K. Gupte-Singh², A.J. Belli³, D.C. Lane³, A. Lakshmanan⁴, A.D. Norden³, ¹Cota Healthcare, Boston, US, ²Bristol-Myers Squibb, Princeton, US, ³COTA, Boston, US, ⁴Cota, Boston, US
- 12:15 - 12:15 **75P - Immune-related toxicities in NSCLC: Real-world experience from a tertiary cancer center**
P.D. D'Arienzo¹, A. Olsson-Brown², M. Sallam³, A. Ortega-Franco², H. Wong², C. Escriu², ¹The Christie NHS Foundation Trust, Manchester, GB, ²Clatterbridge Cancer Center - NHS Foundation Trust, Wirral, GB, ³University of Liverpool, Liverpool, GB
- 12:15 - 12:15 **76P - Real-world data analysis of PD-L1 expression and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)**
J. Staib¹, S. Sudarsanam², S. Dacosta Byfield³, C. Kennedy¹, L. Weiss², ¹UnitedHealth Group, Minnetonka, US, ²NeoGenomics Laboratories, Aliso Viejo, US, ³United Health Group, Minnetonka, US
- 12:15 - 12:15 **77P - The characteristics of long-lasting responders to PD-1 inhibitor in advanced non-small cell lung cancer patients**
H. Jo¹, T. Yoshida², S. Yagishita³, Y. Shinno⁴, Y. Okuma⁵, Y. Goto⁴, H. Horinouchi⁶, N. Yamamoto⁴, Y. Ohe⁶, ¹National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP, ²Aichi Cancer Center Hospital, Nagoya, JP, ³Juntendo University Hospital, Tokyo, JP, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, ⁶National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP
- 12:15 - 12:15 **78P - A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM)**
M. Tagliamento¹, P. Bironzo¹, E. De Luca², D. Pignataro¹, S. Rapetti¹, M. Audisio², V. Bertaglia¹, C. Paratore¹, M. Bungaro¹, E. Olmetto¹, E. Artusio¹, M.L. Reale¹, C. Zichi², E. Capelletto¹, S. Carnio¹, L. Buffoni¹, F. Passiglia¹, S. Novello¹, M. Di Maio², ¹Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, ²Ospedale Ordine Mauriziano, Turin, IT
- 12:15 - 12:15 **79P - Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer**

T. Enomoto¹, A. Tamiya¹, K. Matsumoto¹, Y. Adachi¹, K. Azuma¹, Y. Inagaki¹, S. Kouno¹, Y. Taniguchi¹, N. Saijo¹, K. Okishio¹, S. Atagi², ¹National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, JP, ²Kinki-chuo Chest Medical Center, Sakai, JP

12:15 - 12:15 **80P - Nintedanib (N) & docetaxel (D) after immunotherapy in adenocarcinoma non-small cell lung cancer (NSCLC): First results from the non-interventional LUME-BioNIS study**

M. Reck¹, K. Syrigos², S. Miliuskauskas³, S. Zöchbauer-Müller⁴, H. Buchner⁵, T. Kitzing⁶, K. Kerr⁷, ¹Krankenhaus Grosshansdorf, Grosshansdorf, DE, ²National and Kapodistrian University of Athens - School of Medicine, Athens, GR, ³Hospital of Lithuanian University of Health Sciences, Kaunas, LT, ⁴Department of Medicine I, Vienna, AT, ⁵Staburo GmbH, Munich, DE, ⁶Boehringer Ingelheim - Germany, Biberach, DE, ⁷Aberdeen Royal Infirmary, Aberdeen, GB

12:15 - 12:15 **81P - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) progressing after immune checkpoint inhibitors - AVATAX , a retrospective multicentric study: Preliminary data**

S. Valery¹, C. Chouaid², G. Rousseau-Bussac², I. Monnet², G. Bilger³, P. Boré⁴, J. Pinsolle⁵, R. Descourt⁶, M. Geier⁷, A.C. Toffart⁸, P. Cony-Makhoul⁹, G. Robinet⁶, F. Ennahdi³, I. Zaccaria³, C. Decroisette¹⁰, ¹Paris Descartes University, Paris, FR, ²CH Intercommunal de Créteil, Créteil, FR, ³CH d'Annecy, Annecy, FR, ⁴CHRU de Brest, Brest, FR, ⁵Institut Daniel Hollard, Grenoble, FR, ⁶C.H.U. Brest - Hôpital Morvan, Brest, FR, ⁷CHRU Morvan Brest, Brest, FR, ⁸CHU de Grenoble-Alpes- Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, ⁹Centre Hospitalier Annecy Genevois, Annecy, FR, ¹⁰Le Centre Hospitalier Annecy Genevois, Metz-Tessy, FR

12:15 - 12:15 **82P - Real-world survival with first-line (1L) chemotherapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)**

D. Waterhouse¹, K.A. Betts², J. Zhao³, S. Rao⁴, K. Gupte-Singh⁴, M. Rutstein⁴, M.K. Higashi⁴, L. Schwartzberg⁵, ¹Oncology Hematology Care, Cincinnati, US, ²Analysis Group, Inc., Los Angeles, US, ³Analysis Group, Inc., Denver, US, ⁴Bristol-Myers Squibb, Princeton, US, ⁵West Cancer Center, Germantown, US

12:15 - 12:15 **83P - Analysis of predictive factors in non-small cell lung cancer patients treated with nivolumab**

K. Azuma¹, A. Tamiya¹, Y. Adachi¹, T. Enomoto¹, S. Kouno¹, Y. Taniguchi¹, N. Saijo¹, K. Okishio¹, S. Atagi², ¹National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, JP, ²Kinki-chuo Chest Medical Center, Sakai, JP

12:15 - 12:15 **84P - Survival outcomes in stage IV small-cell lung cancer (IV-SCLC): Analysis from SEER database**

J. De Castro Carpeño¹, M. Cobo Dols², M. Domine Gomez³, P. Ruiz Gracia⁴, L. Crama⁵, M.R. Garcia Campelo⁶, ¹Hospital Universitario La Paz, Madrid, ES, ²Biomedical Research Institute of Málaga (IBIMA), Malaga, ES, ³University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁴Roche Farma S.A., Madrid, ES, ⁵Roche S.A. Q. e I. - Argentina, Ricardo Rojas, AR, ⁶Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES

- 12:15 - 12:15 **85P - Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC)**
O. Schmalz¹, C. Jacob², J. Ammann³, B. Liss⁴, S. Iivanainen⁵, M. Kammermann³, J. Koivunen⁶, M. Giger⁷, A. Klein³, R. Popescu⁸, ¹HELIOS Klinikum Wuppertal, Wuppertal, DE, ²Anglia Ruskin University, Cambridge, GB, ³F. Hoffmann-La Roche Ltd, Basel, CH, ⁴Helios Universitätsklinikum Wuppertal, Wuppertal, DE, ⁵Oulu University Hospital, Oulu, FI, ⁶Oulu University Hospital, Oulu, CH, ⁷Kantonsspital St. Gallen, St. Gallen and Rorschach, CH, ⁸Hirslanden Klinik Aarau, Aarau, CH
- 12:15 - 12:15 **86P - A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC**
G. Viscardi¹, F. Sparano¹, R. Di Liello¹, G. Alonso Casal², R. Borrás Ferreres³, G. Bruixola³, V. Gambardella³, N. Zanaletti¹, M.L. Iacovino¹, C.M. Della Corte¹, F. Papaccio¹, M. Fasano¹, F. Ciardiello¹, A. Cervantes³, F. Morgillo¹, P. Martin Martorell³, M.A. Insa Molla³, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Hospital Clínico Universitario de Valencia, Valencia, ES
- 12:15 - 12:15 **87P - Clinical outcomes of metastatic melanoma patients treated with ipilimumab and nivolumab: A single institution experience**
H.K. Oberoi Oberoi¹, C. Vila², A. Rodriguez³, D. Pesantez Coronel⁴, F. Aya Moreno⁵, M.C. Font Puig⁶, A.M. Arance Fernandez⁶, ¹Hospital Clínic of Barcelona, Barcelona, ES, ²Hospital de Sabadell Corporació Parc Tauli, Sabadell, ES, ³Institut Clínic de Malalties Hematològiques i Oncològiques, Barcelona, ES, ⁴Atlanta Viajes SA, Barcelona, ES, ⁵Centre for Genomic Regulation (CRG), Barcelona, ES, ⁶Hospital Clínic y Provincial de Barcelona, Barcelona, ES
- 12:15 - 12:15 **88P - A study on analysis of clinical efficacy factor and exploring prognostic factors for reimbursement policy after immunotherapy being introduced in South Korea**
J. Yi, Health insurance review & assessment service, Seoul, KR
- 12:15 - 12:15 **89TiP - Arginase-1 Peptide Vaccine in Patients with Metastatic Solid Tumors**
C.L. Lorentzen, M. Andersen, I.M. Svane, Herlev Hospital, Herlev, DK
- 12:15 - 12:15 **90TiP - FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03)**
J. Fayette, Centre Léon Bérard, Lyon, FR
- 12:15 - 12:15 **96P - Clearance of HPV anal premalignant lesions and modulation of systemic immune responses to HPV oncogenes with low dose pomalidomide**
M. Polizzotto¹, D. Van Bockel², C. Law³, J. Roberts⁴, G. Buckland², S. Just¹, S. Comben³, R. Hillman³, R. Gilson⁵, S. Pett⁶, M. Poynten¹, M. Law¹, A. Kelleher¹, S. Emery¹, ¹Kirby Institute, UNSW Sydney, Sydney, AU, ²Kirby Institute, UNSW Sydney, Surry Hills, AU, ³St Vincent's Hospital Sydney, Sydney, AU, ⁴Douglass Hanly Moir Pathology, Sydney, AU,

⁵Mortimer Market Center, London, GB, ⁶Medical Research Council, London, GB

12:15 - 12:15

97P - Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC)

D. Rischin¹, N.I. Khushalani², C.D. Schmults³, A. Guminski⁴, A.L. Chang⁵, K.D. Lewis⁶, A.M. Lim⁷, L. Hernandez-Aya⁸, B.G.M. Hughes⁹, D. Schadendorf¹⁰, A. Hauschild¹¹, E. Stankevich¹², J. Booth¹³, S. Li¹², Z. Chen¹², J. Desai¹², I. Lowy¹², M.G. Fury¹², M.R. Migden¹⁴, ¹Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, AU, ²Moffitt Cancer Center, Tampa, US, ³Brigham and Women's Hospital, Harvard Medical School, Boston, US, ⁴Royal North Shore Hospital, St Leonards, AU, ⁵Stanford University School of Medicine, Redwood City, US, ⁶University of Colorado Comprehensive Cancer Center, Aurora, US, ⁷Sir Charles Gairdner Hospital, Perth, AU, ⁸Washington University School of Medicine, St. Louis, US, ⁹and University of Queensland, Brisbane, AU, ¹⁰University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ¹¹Schleswig-Holstein University Hospital, Kiel, DE, ¹²Regeneron Pharmaceuticals, Inc., Tarrytown, US, ¹³Regeneron Pharmaceuticals, Inc., Basking Ridge, US, ¹⁴University of Texas MD Anderson Cancer Center, Houston, US

12:15 - 12:15

98P - Results from a phase I study of MK-1308 (anti-CTLA-4) plus pembrolizumab in previously treated advanced small cell lung cancer

B.C. Cho¹, K. Yoh², J. Bar³, A. Nagrial⁴, D. Spigel⁵, M. Gutierrez⁶, D.-W. Kim⁷, D. Kotasek⁸, D. Rasco⁹, J. Niu¹⁰, M. Satouchi¹¹, M.-J. Ahn¹², D.H. Lee¹³, C. Maurice-Dror¹⁴, S. Siddiqi¹⁵, X. Li¹⁵, J. Cyrus¹⁵, R. Altura¹⁵, R. Perets¹⁴, ¹Yonsei University, Seoul, KR, ²National Cancer Center Hospital East, Kashiwa, JP, ³Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, IL, ⁴Blacktown Hospital and University of Sydney, Sydney, AU, ⁵Sarah Cannon Research Institute, Nashville, US, ⁶Hackensack University Medical Center, Hackensack, US, ⁷Seoul National University Hospital, Seoul, KR, ⁸Adelaide Cancer Centre and University of Adelaide, Kurrulta Park, AU, ⁹START, San Antonio, US, ¹⁰Banner MD Anderson Cancer Center, Gilbert, US, ¹¹Hyogo Cancer Center, Akashi, JP, ¹²Sungkyunkwan University of Medicine, Samsung Medical Center, Seoul, KR, ¹³University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, ¹⁴Rambam Medical Center, Haifa, IL, ¹⁵Merck & Co., Inc., Kenilworth, US

12:15 - 12:15

99P - A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3/CD276 and PVR/CD155

B. Husain¹, N. Martinez-Martin², ¹Genentech, San Francisco, US, ²Genentech, Inc., South San Francisco, US

12:15 - 12:15

100P - Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer

I. Marquez-Rodas¹, F. Longo², S. Ponce Aix³, M. Jove⁴, B. Rubio⁵, A. Calles Blanco⁶, M.E. Rodriguez-Ruiz⁷, M. Ponz-Sarvisé⁸, E. Castañón⁸, P. Gajate², C. Sempere-Ortega², E. Jimenez-Aguilar³, P. Lopez-Casas⁹, E. De Miguel¹⁰, R. Ramos-Medina¹¹, A. Calvo¹¹, M. Martin¹¹, D. Tersago⁹, M. Quintero⁹, I. Melero⁸, ¹Hospital General Universitario Gregorio Marañón - Fundación Investigación Biomedica, Madrid, ES, ²Hospital Ramón y Cajal, IRYCIS, CiberOnc, Madrid, ES, ³University Hospital 12 De Octubre, Madrid, ES,

⁴Institut Català d'Oncologia, Madrid, ES, ⁵Hospital Universitario Quirónsalud, Madrid, ES, ⁶Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁷CIMA & Clínica Universidad de Navarra, Pamplona, ES, ⁸Clinica Universitaria de Navarra, Pamplona, ES, ⁹Bioncotech, Valencia, ES, ¹⁰Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM). Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹¹Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM). CiberOnc, Hospital General Universitario Gregorio Marañón, Madrid, ES

12:15 - 12:15

101P - Results of the NLG2105 phase I trial using the IDO pathway inhibitor indoximod, in combination with radiation and chemotherapy, for children with newly diagnosed DIPG

T. Johnson¹, D. Aguilera², A. Al-Basheer¹, Z. Berrong¹, R. Castellino², B. Eaton², N. Esiashvili², N. Foreman³, I. Heger⁴, E. Kennedy⁵, N. Vahanian⁵, W. Martin¹, R. Pacholczyk¹, E. Ring¹, R. Sadek¹, A. Smith⁶, M. Shimoda¹, T. Macdonald², D. Munn¹, ¹Augusta University, Augusta, US, ²Emory University, Atlanta, US, ³Children's Hospital Colorado, Aurora, US, ⁴Medical City Children's Hospital, Dallas, US, ⁵NewLink Genetics Corporation, Ames, US, ⁶Arnold Palmer Hospital for Children, Orlando, US

12:15 - 12:15

102P - Results from a phase II trial of pembrolizumab (P) plus gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study

L. De La Cruz Merino¹, J. Cruz², J.L. Alonso³, V. Quiroga Garcia⁴, F. Moreno Anton⁵, R. Andres⁶, M. Santiesteban⁷, M. Ramos Vazquez⁸, M. Gion Cortes⁹, J. Cortés¹⁰, N. Palazon Carrion¹, I. Ceballos Lenza¹¹, A. Soto¹², M. Casas¹³, S. Benito¹⁴, S. Bezares Montes¹⁵, E. Holgado¹⁶, ¹Hospital Universitario Virgen Macarena, Sevilla, ES, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, ES, ³IMIB-Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, ES, ⁴Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ⁵Hospital Clinico Universitario San Carlos, Madrid, ES, ⁶Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ⁷Clínica Universidad de Navarra, Pamplona, ES, ⁸Fundacion Centro Oncologico de Galicia, A Coruña, ES, ⁹Hospital Universitario Ramon y Cajal, Madrid, ES, ¹⁰IOB Institute of Oncology; Vall d'Hebron Institute of Oncology., Barcelona, ES, ¹¹Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ¹²Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, ES, ¹³GEICAM Spanish Breast Cancer Group, San Sebastian de los Reyes, ES, ¹⁴GEICAM-Spanish Breast Cancer Research Group, San Sebastian de los Reyes, ES, ¹⁵GEICAM, San Sebastian de los Reyes, ES, ¹⁶IOB Institute of Oncology, Hospital Riber Juan Bravo, Madrid, ES

12:15 - 12:15

103P - Combinatorial unique photothermal tumour immunotherapy against targeted triple negative breast cancer therapy of dual modal nanoplatfom

V. Raju¹, V. Yasothamani¹, S. Shyamsivappan¹, Y. Haldorai¹, K. Saravanakumar², ¹Bharathiar University, Coimbatore, IN, ²Kangwon National University, Chuncheon, KR

12:15 - 12:15

104P - A novel immunological role of hydrogen sulphide in shaping natural killer cells cytotoxicity in breast cancer patients

R. Youness¹, A. Abdelmotaal², M. Gad¹, ¹German University in Cairo, Cairo, EG, ²Faculty of Pharmacy, King Khalid University, Abha, SA

- 12:15 - 12:15 **105P - Discovery of bioactive small molecule inhibitors of human PD1-PDL1 interaction**
S. Patil, J. Difflumeri, E. Fattakhova, Widener University, Chester, US
- 12:15 - 12:15 **106P - A single dose of local IL-12 promotes anti-tumor effect of anti-EGFRvIII-CAR-T cells in a syngeneic murine model of glioblastoma**
A.R. Liuzzi¹, G. Agliardi², B. Becher¹, M. Pule³, ¹UZH - University of Zurich - Irchel Campus, Zurich, CH, ²University of Zurich, CH-, CH, ³Cancer Institute, London, CH
- 12:15 - 12:15 **107P - Increasing responses to T-cell therapies in solid tumours by the use of an engineered adenovirus coding for TNFa and IL-2**
V. Cervera-Carrascon¹, R. Havunen², J.M. Santos³, D. Quixabeira³, A. Hemminki², S. Zafar³, ¹University of Helsinki-Faculty of medicine, Helsinki, FI, ²University of Helsinki and TILT Biotherapeutics, Helsinki, FI, ³University of Helsinki, Helsinki, FI
- 12:15 - 12:15 **108P - Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances Th1 cytokine production**
M. Gavin, A. Gragerov, E. Espling, A. Rohde, T. Sexton, C. Douлами, G. Gaitanaris, Omeros Corporation, Seattle, US
- 12:15 - 12:15 **109P - Phase I clinical study for validation of fimaporfin-based photochemical internalisation: A novel technology for enhancing cellular immune responses important for therapeutic effect of peptide-and protein-based vaccines**
P.K. Selbo¹, S. Janetzki², M. Welters³, M. Håkerud¹, A. Nedberg¹, V. Edwards¹, H. Olivecrona⁴, S.H. Van Der Burg³, T. Otterhaug⁴, A. Hogset⁴, ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ²ZellNet Consulting, Inc., Fort Lee, US, ³Leiden University Medical Center, Leiden, NL, ⁴PCI Biotech AS, Oslo, NO
- 12:15 - 12:15 **111P - Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors**
S. Moerk¹, M. Donia², J. Kringelum³, T. Bogenrieder³, B. Rønø³, A. Sorensen³, A. Draghi², K. Bol¹, N. Petersen³, M. Kadivar⁴, S. Hernandez⁴, S. Reker Hadrup⁵, L. Andreasen⁶, D. Christensen⁶, P. Andersen², I.M. Svane¹, ¹Herlev Hospital, Herlev, DK, ²Herlev Hospital - National Center for Cancer Immune Therapy, Herlev, DK, ³Evaxion, Copenhagen K, DK, ⁴DTU Health Technology, Kgs. Lyngby, DK, ⁵National Veterinary Institute (DTU Vet), Copenhagen, DK, ⁶Statens Serums Institut, Kbh. S, DK
- 12:15 - 12:15 **112P - Identification of a novel promiscuous anti-NY-ESO-1 immunogenic CD4&&**
M. Merhi¹, A. Raza¹, V. Inchakalody¹, S. Sivaraman², F. Panayampilly², S. Mestiri¹, S. Hydrose¹, N. Allahverdi¹, M. Jalis¹, A. Relecom¹, L. Al Zaidan¹, J. Feilchenfeldt³, M.S. Elkhatim Hamid¹, M. Mostafa¹, A.R. Zar Gul¹, S.U. Khan², S. Dermime¹, ¹Hamad Medical Corporation (HMC)-National Center for Cancer Care and Research (Al Amal Hospital), Doha, QA, ²Hamad Medical Corporation, Doha, QA, ³Hôpital Riviera Chablais, vevey, CH
- 12:15 - 12:15 **113P - A phase I study of an anti-IDO1 inhibitor (LY3381916) as monotherapy**

and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer

N. Kotecki¹, B. O'Neil², S. Jalal³, C. Massard⁴, J. Wallin⁵, A. Szpurka⁶, D. Wang⁶, V. Regnier Galvao⁶, M. Xia⁶, K. Crowe⁶, S. Geeganage⁶, T. Doman⁶, L. Gandhi⁷, X. Xu⁷, J. Bendell⁸, ¹Syneos Health - Corporate Headquarters, Morrisville, US, ²Indiana University Simon Cancer Center, Indianapolis, US, ³Indiana University, Indianapolis, US, ⁴Institut Gustave Roussy, Paris, FR, ⁵Eli Lilly and Company, Stockholm, SE, ⁶Eli Lilly and Company, Indianapolis, US, ⁷Eli Lilly and Company, New York, US, ⁸Sarah Cannon Research Institute, Nashville, US

12:15 - 12:15 **114P - Targeting the EGF-receptor and CD38 in solid and haematological malignancies with nanobody-based heavy chain antibodies and AAV vectors**

N. Baum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE

12:15 - 12:15 **115P - Therapeutic efficacy of combining the tumour checkpoint controller BAL101553 (lisavanbulin) and immunomodulation in two mouse glioma models with different immunological status**

V. Genoud¹, E. Marinari¹, V. Bes¹, P.-Y. Dietrich², P. Mcsheehy³, F. Bachmann⁴, H. Lane⁴, P. Walker², ¹Université de Genève (UNIGE) - Centre Médical Universitaire (CMU), Geneva, CH, ²Hôpitaux Universitaires de Genève - HUG, Geneva, CH, ³Novartis Pharma AG, Basel, CH, ⁴Basilea Pharmaceutica International Ltd, Basel, CH

12:15 - 12:15 **116P - Development of advanced human immune system mouse models for pre-clinical research in immuno-oncology**

A. Mossu, B. Tschumi, TransCure bioServices, Archamps, FR

12:15 - 12:15 **117P - Immune checkpoint inhibitors (ICI) in combination with chemotherapy as first-line (1L) treatment for non-small cell lung cancer (NSCLC): A pair-wise meta-analysis (MA)**

F.J. Afonso-Afonso¹, M. Amenedo Gancedo², M.C. Areses Manrique³, B. Campos Balea⁴, J. Casal Rubio⁵, N. Fernández-Núñez⁶, J.L. Firvida Perez⁷, J. García González⁸, M. Lázaro Quintela⁹, L. León-Mateos¹⁰, J. Ruíz-Bañobre¹¹, D. Pérez Parente¹², L. Crama¹³, P. Ruiz Gracia¹⁴, L. Santomé Couto¹⁵, ¹Complejo Hospitalario Arquitecto Marcide-Prof. Novoa Santos, A Coruña, ES, ²Fundacion Centro Oncologico de Galicia, A Coruña, ES, ³Complejo Hospitalario De Ourense, Ourense, ES, ⁴Hospital Universitario Lucus Augusti (HULA), Lugo, ES, ⁵Hospital Meixoeiro, Vigo, ES, ⁶Hospital Universitario Lucus Agusti, Lugo, ES, ⁷Centro Médico El Carmen, Ourense, ES, ⁸Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Santiago de Compostela, ES, ⁹Hospital Alvaro Cunqueiro, Pontevedra, ES, ¹⁰Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Santiago de Compostela, ES, ¹¹Complejo Hospitalario Universitario de Ferrol, Ferrol, ES, ¹²Roche Farma S.A, Madrid, ES, ¹³Roche S.A. Q. e I. - Argentina, Ricardo Rojas, AR, ¹⁴Roche Farma S.A., Madrid, ES, ¹⁵Hospital POVISA, Vigo, ES

12:15 - 12:15 **118P - The role of asunercept as a selective CD95L inhibitor in cutaneous melanoma: Rationale and results from an enhanced TiRP model**

A. Krendyukov¹, N. Kneisel¹, J. Zhu², C. Merz¹, D. Richards¹, C. Gieffers¹, B. Van Den Eynde², ¹Apogenix AG, Heidelberg, DE, ²Ludwig Institute for Cancer Research, Brussels,

BE

- 12:15 - 12:15 **119P - Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma**
S. Tjulandin¹, M. Fedyanin², L. Demidov³, V. Moiseyenko⁴, S. Protsenko⁴, S. Odintsova⁵, T. Semiglazova⁴, R. Zukov⁶, S. Lazarev⁷, A. Andreev⁸, M. Nechaeva⁹, J. Makarova¹⁰, N. Fadeeva¹¹, A. Tarasova¹², O. Kozlova¹³, M. Shustova¹⁴, A. Garipov¹³, R. Ivanov¹³, ¹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ²N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ³MSD Pharmaceuticals, LLC, Moscow, RU, ⁴N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, ⁵Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, ⁶Krasnoyarsk Regional Clinical Oncological Hospital named after A.I.Kryzhanovskiy, Krasnoyarsk, RU, ⁷Altay Regional Oncology Dispensary, Barnaul, RU, ⁸Medical Center of the Federal Medical and Biological Agency, Novosibirsk, RU, ⁹Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, RU, ¹⁰Krasnodar Regional Oncological Centre, Krasnodar, RU, ¹¹Chelyabinsk Regional Oncology Hospital, Chelyabinsk, RU, ¹²Samara Regional Clinical Cancer Centre, Samara, RU, ¹³BIOCAD, Saint-Petersburg, RU, ¹⁴BIOCAD - Biotechnology Company, Saint-Petersburg, RU
- 12:15 - 12:15 **120P - Combination of triptorelin with nivolumab in ICI resistant advanced melanoma**
C. Robert¹, F. Lejeune², C. Lebbé³, T. Lesimple⁴, E. Lundström⁵, V. Nicolas⁵, B. Gavillet⁶, V. Grégoire⁶, P. Crompton⁵, ¹Institut Gustave Roussy, Villejuif, FR, ²Debiopharm International S.A., Lausanne, CH, ³Hopital Saint Louis, Paris, FR, ⁴Centre Eugène Marquis, Rennes, FR, ⁵Debiopharm International SA, Lausanne, CH, ⁶Debiopharm International SA, Lausanne, CH
- 12:15 - 12:15 **121P - Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: Final data**
L. Ridolfi¹, J. Bulgarelli¹, E. Petracci¹, E. Pancisi¹, C. Piccinini¹, A. Granato¹, M. Petrini¹, M. Tazzari¹, V. Ancarani¹, L. Turci¹, G. Gentili¹, L. Valmorri¹, A. Romeo¹, U. De Giorgi², S.L. Burgio¹, C. Casadei¹, P. Cortesi¹, C. Lolli², F. De Rosa², M. Guidoboni², ¹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, ²Istituto Tumori della Romagna I.R.S.T., Meldola, IT
- 12:15 - 12:15 **122P - Local thermal ablation reboots the response in advanced hepatocellular carcinoma with stable or atypical progressive diseases during anti-PD-1 therapy**
M. Zhao¹, J. Huang¹, N. Lyu², Y. Kong¹, L. Mu³, Y. Lin⁴, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, CN, ⁴Jieyang Affiliated Hospital, Sun Yat-sen University, Jieyang, CN
- 12:15 - 12:15 **123P - Patient-Derived Explant Cultures (PDECs) as a model system for immunology studies**
R. Turpin¹, P. Munne², I. Suleymanova¹, S. Mustjoki², J. Pouwels¹, J. Klefström², ¹University of Helsinki - Faculty of medicine, Helsinki, FI, ²University of Helsinki-Faculty of medicine, Helsinki, FI

- 12:15 - 12:15 **124P - A phase I study of percutaneous oncolytic rose bengal disodium for metastatic uveal melanoma patients with hepatic metastases: A single-center cohort summary**
S. Patel¹, B. Carter², G. Balmes², H. Rider², J. Joseph², C. Zobniw², V. Trinh², J. Anderson², R. Sheth², R. Murthy², E. Wachter³, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³Provectus Biopharmaceuticals, Knoxville, US
- 12:15 - 12:15 **125P - Response assessment of metastatic uveal melanoma treated with rose bengal disodium**
B. Carter¹, R. Murthy¹, G. Balmes¹, E. Wachter², S. Patel³, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Provectus Biopharmaceuticals, Knoxville, US, ³The University of Texas MD Anderson Cancer Center, Houston, US
- 12:15 - 12:15 **126TiP - A phase I study of NBTXR3 activated by radiotherapy for patients with advanced cancers treated with an anti-PD-1 therapy**
C. Shen¹, K. Jameson², J. Weiss¹, T. Hackman³, D. Corum², J.A. Akulian³, R. Dixon¹, A. Pearson⁴, J. Frakes⁵, P. Said⁶, H. Miraoui², E. Baskin-Bey⁶, T. Seiwert⁷, ¹University of North Carolina, Chapel Hill, US, ²Nanobiotix SA, Cambridge, US, ³University of North Carolina at Chapel Hill, Chapel Hill, US, ⁴University of Chicago, Chicago, US, ⁵Moffitt Cancer Center, Tampa, US, ⁶Nanobiotix SA, Paris, FR, ⁷Johns Hopkins, Baltimore, US
- 12:15 - 12:15 **127TiP - PROPEL: A phase I/II trial of bempedalesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours**
M. Reck¹, F. Cappuzzo², D. Rodriguez-Abreu³, D. Cho⁴, J. Schwarz⁵, M. Riese⁶, A. Gupta⁷, T. Chan⁷, R. Saab⁷, S. Singel⁷, W. Lin⁷, M. Tagliaferri⁷, D. Spigel⁸, ¹Krankenhaus Grosshansdorf, Grosshansdorf, DE, ²AUSL della Romagna-Ravenna, Ravenna, IT, ³Hospital Universitario Insular de Gran Canaria, Gran Canaria, ES, ⁴Perlmutter Cancer Center NYU Langone, New York, US, ⁵University of Nebraska Medical Center, Omaha, US, ⁶Medical College of Wisconsin, Milwaukee, US, ⁷Nektar Therapeutics, San Francisco, US, ⁸Sarah Cannon Research Institute, Nashville, US
- 12:15 - 12:15 **128TiP - VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial**
M. Jove¹, I. Braña², M. Taberna³, A. Hernando-Calvo², J. Brenes Castro³, E. Garralda⁴, M. Plana Serrahima³, M. Maños Pujol⁵, G. Capella³, R. Alemany⁶, E. Blasi⁷, C. Blasco⁸, M. Cascallo Piqueras⁸, R. Mesia Nin⁹, ¹Institut Català d'Oncologia, Madrid, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁵Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, ES, ⁶Institut Català de Oncologia, Barcelona, ES, ⁷VCN Biosciences, Sant Cugat del Valles, ES, ⁸VCN BIOSCIENCES SL, Barcelona, ES, ⁹Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES
- 12:15 - 12:15 **131P - PD-1 and LAG-3 synergize to drive tumour-infiltration of T cytotoxic cells in NSCLC tumours**

A. Juncker-Jensen, M. Nagy, J. Kuo, E. Leones, F. Sahafi, K. Pham, E. Parnell, NeoGenomics, Aliso Viejo, US

- 12:15 - 12:15 **132P - Correlation between tumour infiltration lymphocyte and PDL-1 expression in laryngeal cancer and its prognostic significance: A prospective, non-interventional trial**
M. Ismail¹, H. El Wakiel¹, D. Abd El Ghany¹, M. Shakweer¹, A. Lotfy¹, A. Gaballah², ¹Ain Shams University Specialized Hospital, Cairo, EG, ²Ain Shams university Faculty of medicine, Cairo, EG
- 12:15 - 12:15 **133P - Tumour immune infiltrate characterization in luminal breast cancer in three distinct age categories and its correlation with frailty**
L. Berben¹, H. Wildiers², C. Kenis¹, B. Dalmasso³, A. Smeets², H. Vos¹, P. Neven², G. Floris², S. Hatse², ¹KU Leuven, Leuven, BE, ²University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ³University of Genoa and Ospedale Policlinico San Martino, Genoa, IT
- 12:15 - 12:15 **134P - Comprehensive assessment of anti-tumour PDL1 blockade effect in a sarcoma mouse model**
I. Nafia¹, A. Chaibi¹, D. Bortolotto¹, L. Cerf¹, A. Italiano², A. Bessede¹, ¹Explicyte, Bordeaux, FR, ²Institute Bergonié, Bordeaux, FR
- 12:15 - 12:15 **135P - Analysis of the immune microenvironment in pre-treatment non-small cell lung cancer (NSCLC) patients with follow-up response data to second-line immunotherapy**
M. Bhagat¹, S. Warren², N. Elliott², C. Womack¹, L. Memeo¹, L. Colarossi¹, M. Cumberbatch³, ¹Tristar Technology Group, Washington, US, ²NanoString Technologies, Seattle, US, ³Immune Insight Limited, Alderley Edge, GB
- 12:15 - 12:15 **136P - Profiling the tumour immune microenvironment in pleomorphic dermal sarcomas suggests its potential effectiveness for immunotherapy**
K.-W. Noh, S. Klein, C. Mauch, S. Wagener-Ryzek, M. Schoemmel, R. Buettner, A. Quaas, D. Helbig, University Hospital Cologne, Köln, DE
- 12:15 - 12:15 **137P - Comparative analysis of the immune microenvironment in histological subtypes of lung and breast cancer using a tissue microarray (TMA) comprising invasive margin (IM) and tumour centre (TC)**
M. Cumberbatch¹, L. Memeo², C. Womack², W. Kim³, M. Bhagat², ¹Immune Insight Limited, Alderley Edge, GB, ²Tristar Technology Group, Washington, US, ³Seoul National University Medical College, Seoul, KR
- 12:15 - 12:15 **138P - Prognostic implications of residual disease tumour-infiltrating lymphocytes in gastric cancer patients after neoadjuvant chemotherapy**
X. Xing¹, S. Jia², Y. Feng¹, M. Zhang¹, J. Ji², ¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, ²Peking University Cancer Hospital, Beijing, CN
- 12:15 - 12:15 **139P - Multiplex IHC panel development for adenosine pathway markers and TIL**

in human cancer specimens

A. Pabois¹, V. Bodo¹, A. Boisson², S. Crosignani¹, O. De Henau¹, M. Detheux³, S. Garaud², J. Lager³, C. Martinoli¹, M. Mercier¹, C. Naveaux², N. Thomas², N. Wald¹, A. Vezzu¹, K. Willard-Gallo², E. Houthuys¹, ¹iTeos Therapeutics, Gosselies, BE, ²Institute Jules Bordet, Brussels, BE, ³iTeos Therapeutics, Cambridge, US

12:15 - 12:15 **140P - B-cell clusters in the stroma at invasive tumour margin provide prognostic value in early-stage oral-tongue cancer patients: The discovery and validation study**

C. Phanthunane¹, R. Wijers², M. De Herdt², J. Hardillo², S. Sleijfer³, S. Koljenovic², S. Desgupta², E. Balcioglu², R. Debets⁴, R. Baatenburg De Jong², ¹Chulabhorn Hospital, Bangkok, TH, ²ErasmusMC, Rotterdam, NL, ³Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ⁴Erasmus University Medical Center, Rotterdam, NL

12:15 - 12:15 **141P - Identifying mechanisms of macrophage-mediated metastasis and treatment resistance in pancreatic cancer**

T. Wu, CRUK Cambridge Institute, Cambridge, GB

12:15 - 12:15 **142P - Association of MUC16 mutation with survival of immune checkpoint inhibitor in patients with cancer**

Q. Ou¹, D. Lin², Y. Yu¹, A. Li³, W. Zhang³, Y. Chen⁴, R. Liu³, Y. Tan¹, M. Xu¹, L. Li², H. Yao¹, ¹Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, ²Sun Yat-Sen University Cancer Center, Guangzhou, CN, ³Guangdong Medical University, Zhanjiang, CN, ⁴The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN

12:15 - 12:15 **143P - Association of PTPRT mutation with survival of immune checkpoint inhibitor in patients with cancer**

A. Li¹, D. Lin², Y. Yu³, Y. Gu³, Q. Ou³, W. Zhang¹, Y. Chen⁴, R. Liu¹, Y. Tan³, H. Xu³, L. Li², H. Yao³, ¹Guangdong Medical University, Zhanjiang, CN, ²Sun Yat-Sen University Cancer Center, Guangzhou, CN, ³Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, ⁴The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN

12:15 - 12:15 **144P - Loss of BAP-1 influences the activation of p52 and RelB proteins in the Inflammatory microenvironment of uveal melanoma**

M. Singh¹, S. Kashyap², L. Singh³, N. Pushker⁴, S. Bakhshi², S. Sen¹, ¹All India Institute of Medical Sciences, Delhi, IN, ²All India Institute of Medical Sciences, New Delhi, IN, ³Jamia Millia Islamia, New Delhi, IN, ⁴All India Institute of Medical Sciences, New delhi, IN

12:15 - 12:15 **145P - Immune-competent 3D InSight™ tumour models as novel platform to assess combinatorial biologics therapy**

F. Chiovaro, N. Buschmann, S. Strebel, A. Wolf, I. Agarkova, InSphero AG, Schlieren, CH

12:15 - 12:15 **146P - The dynamics between neo-adjuvant treatment and immune responses in human breast cancer**

N. Thomas¹, S. Garaud¹, A. De Wind¹, A. Pabois², P. De Silva¹, L. Craciun¹, A. Boisson¹, C. Naveaux¹, H. Duvillier¹, D. Larsimont¹, A. Awada¹, K. Willard-Gallo¹, ¹Institute Jules

Bordet, Brussels, BE, ²iTeos Therapeutics, Gosselies, BE

- 12:15 - 12:15 **147P - A personalised approach for anti-GITR-based immunotherapy in pre-clinical models of pancreatic ductal adenocarcinoma**
- K. Desai¹, C. Ragulan², P.V. Lawrence³, S. Wullschleger⁴, M.L. Tichet⁴, G. Box³, E. Fontana³, K. Young⁵, J. Larkin⁵, D. Hanahan⁴, D. Cunningham⁵, N. Starling⁵, A. Sadanandam³, ¹ICR - The Institute of Cancer Research - North Site, Sutton, GB, ²Institute of Cancer Research, NG, GB, ³Institute of Cancer Research, Sutton, GB, ⁴Swiss Institute of Experimental Cancer Research, EPFL, Lausanne, CH, ⁵The Royal Marsden NHS Foundation Trust, Sutton, GB
- 12:15 - 12:15 **148P - NKG2E comprises an immunogenic peptide, derived from an alu-retrotransposon: An attractive novel target for immunotherapeutic approaches**
- S. Papamichos, Landeskrankenhaus Salzburg, Salzburg, AT
- 12:15 - 12:15 **149P - Revamping the ovarian tumour microenvironment with an oncolytic adenovirus yields enhanced tumour-infiltrating lymphocyte anti-tumour activity**
- J.M. Santos¹, C. Heiniö², V. Cervera-Carrascon³, M. Siurala⁴, D.C.A. Quixabeira², T. De Gruijl⁵, H. Lassus⁶, A. Kanerva⁶, A. Hemminki⁷, ¹University of Helsinki, Helsinki, FI, ²University of Helsinki - Cancer Gene Therapy Group, Helsinki, FI, ³University of Helsinki-Faculty of medicine, Helsinki, FI, ⁴TILT Biotherapeutics Ltd, Helsinki, FI, ⁵University Medical Center Amsterdam - Cancer Center Amsterdam, Amsterdam, NL, ⁶University of Helsinki and Helsinki University Hospital, Helsinki, FI, ⁷University of Helsinki and TILT Biotherapeutics, Helsinki, FI
- 12:15 - 12:15 **150P - Intratumoural MDSC recruitment by chemotherapeutic agent, 5-FU offsets the anti-tumor activity of immune-checkpoint inhibitor in HCC**
- T.T. Kwong¹, C.H. Wong¹, J.Y. Zhou², A.S.-L. Cheng², A.W.H. Chan¹, S.L. Chan¹, ¹The Chinese University of Hong Kong, Shatin, HK, ²The Chinese University of Hong Kong, N.T., HK
- 12:15 - 12:15 **151P - Investigation of the mechanism of action of anti-PD-1 treatment by systematic depletion of different immune cell populations in syngeneic models**
- L. Bourre¹, Y. Jin², J. Muntel³, H. Yu³, K. Beeler³, R. Bruderer³, Y. Shan², A. Xiaoyu An², D. Xuesong Ouyang², H. Qixiang Li², ¹Crown Bioscience Inc., San Diego, US, ²Crown Bioscience Inc, San Diego, US, ³Biognosys AG, Schlieren, CH
- 12:15 - 12:15 **152P - Replicative potency of oncolytic VSV-GP differentially shapes the immune signature in three distinct syngeneic tumour models**
- G. Wollmann¹, B. Spiesschaert², K. Das², L.-M. Schreiber², P. Erlmann³, B. Stierstorfer⁴, D. Von Laer², P. Mueller⁴, C. Urbiola², ¹Innsbruck Medical University, Innsbruck, AT, ²Medical University Innsbruck, Innsbruck, AT, ³Boehringer Ingelheim, Innsbruck, AT, ⁴Boehringer Ingelheim, Biberach, DE
- 12:15 - 12:15 **153P - Immune-microbial crosstalk in oral epithelium: A potential role in oral carcinogenesis?**

A. Salem¹, K. Eklund², ¹HUS Helsinki University Hospital, Helsinki, FI, ²University of Helsinki, Helsinki, FI

- 12:15 - 12:15 **154P - ER stress of cancer cell SCC25 induces LOX-1-expressed immunosuppressive neutrophils**
C.-F. Wu¹, C.-C. Wang², T.-S. Tai², Y.-C. Su³, ¹E-DA Cancer Hospital, Kaohsiung City, TW, ²E-DA Hospital, Kaohsiung City, TW, ³Kaohsiung Municipal Siaogang Hospital, Kaohsiung City, TW
- 12:15 - 12:15 **155P - Interleukin 17F and vasculogenic mimicry: Potential therapeutic targets in oral tongue cancer?**
R. Almahmoudi, University of Helsinki, Helsinki, FI
- 12:15 - 12:15 **156P - T-cell and B-cell intratumoural interactions affect the progression of oropharyngeal squamous cell carcinoma**
K. Hladikova¹, V. Koucky², J. Boucek², J. Laco³, M. Grega², A. Ryska³, R. Spisek⁴, A. Fialova⁴, ¹Charles University - Second Faculty of Medicine (2. LF UK), Prague, CZ, ²Charles University and Motol University Hospital, Prague, CZ, ³Charles University Faculty of Medicine and University Hospital, Hradec Králové, CZ, ⁴Sotio a.s., Prague, CZ
- 12:15 - 12:15 **157P - (Withdrawn)**
- 12:15 - 12:15 **158P - Role of iron metabolism in the immunosuppression mediated by myeloid cells in glioblastoma patients**
S. Magri¹, L. Pinton², E. Masetto², S. Cassandro¹, A. Pozzuoli³, E. Belluzzi³, A. Della Puppa⁴, S. Mandruzzato³, ¹University of Padua, School of Medicine, Padova, IT, ²Veneto Institute of Oncology, Padova, IT, ³University of Padua, Padova, IT, ⁴University of Florence, Firenze, IT
- 12:15 - 12:15 **159P - Supportive roles of microglia in breast cancer brain metastases**
B. Kaminska¹, K. Wojnicki¹, A. Kochalska¹, T. Czernicki², E. Matyja³, W. Grajkowska⁴, ¹Nencki Institute of Experimental Biology, Warsaw, PL, ²Medical University of Warsaw, Warsaw, PL, ³MOssakowski Medical Research Cenetr, Warsaw, PL, ⁴The Children's Memorial Health Institute, Warsaw, PL
- 12:15 - 12:15 **160P - Novel arginase inhibitor alone and in combination with an immune check point inhibitor reduces tumour growth in murine experimental gliomas**
P. Pilanc-Kudlek¹, S. Cyranowski², K. Wojnicki¹, N. Ochocka², M. Grzybowski³, P. Stańczak³, P. Pomper³, R. Błaszczyk³, A. Gołębiowski³, P. Dobrzański³, B. Kaminska¹, ¹Nencki Institute of Experimental Biology, Warsaw, PL, ²Nencki Institute of Experimental Biology, Warszawa, PL, ³OncoArendi Therapeutic SA, Warsaw, PL
- 12:15 - 12:15 **161P - Regulatory interacting network between the immunomodulatory non-coding RNAs: miR-17-5p, MALAT1 and H19 lncRNAs in modulating the tumour microenvironment in TNBC**
R. Soliman, R. Youness, M. El-Shazly, H. Handoussa, M. Gad, German University in Cairo,

Cairo, EG

- 12:15 - 12:15 **162TiP - A phase I study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as standalone and in combination with BI 754091, a programmed death-1 (PD-1) inhibitor, in patients with advanced solid tumours**
A. Marabelle¹, P. Cassier², J.-P. Delord³, C. Jungles⁴, S. Champiat⁵, A. Vinceneux², I. Korakis³, R. Huhn⁶, N. Poirier⁷, B. Vasseur⁸, N. Kotecki⁹, ¹Institut Gustave Roussy, Villejuif, FR, ²Centre Léon Bérard, Lyon, FR, ³Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ⁴Institut Jules Bordet, Brussels, BE, ⁵Gustave Roussy, Villejuif, FR, ⁶Boehringer Ingelheim, US, ⁷OSE Immunotherapeutics, Nantes, FR, ⁸OSE Immunotherapeutics, Paris, FR, ⁹Institute Jules Bordet, Brussels, BE
- 12:15 - 12:15 **164P - Combined detection of CD137 and type 1 functions improves identification and characterization of the activated T lymphocyte repertoire**
A. Draghi¹, A. Gokuldass², C.A. Chamberlain³, H.D. Radic³, I.M. Svane², M. Donia¹, ¹Herlev Hospital - National Center for Cancer Immune Therapy, Herlev, DK, ²Herlev Hospital, Herlev, DK, ³Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK
- 12:15 - 12:15 **165P - Pre-therapeutic evaluation of patient-specific responses to immune-checkpoint inhibition in colorectal cancer**
T. Sturmheit¹, L. Konczalla², T. Sutus Temovski¹, A. Günther², F. Brauneck², J. Li², D. Perez², M. Jücker², J. Thastrup³, W. Fiedler², J. Wellbrock², J. Kupper¹, A. Block², ¹cureX GmbH, Hamburg, DE, ²University Medical Center Hamburg-Eppendorf, Hamburg, DE, ³cureX AS, Copenhagen, DK
- 12:15 - 12:15 **166P - Insights in the mode of action of a T cell bispecific antibody in tumour bearing mice**
A.M. Giusti, J. Sam, M. Karagianni, A. Schneider, Roche Glycart AG, Schlieren, CH
- 12:15 - 12:15 **167P - Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)**
A. Hernando-Calvo¹, O. Mirallas¹, D. Marmolejo¹, E. Felip², E. Garralda³, G. Villacampa Javierre⁴, B. Feliu³, S. Martínez³, R. Gutierrez³, R. Dienstmann¹, I. Braña¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 12:15 - 12:15 **168P - Analysis of endpoints used for FDA approvals of checkpoint inhibitors**
L. Mendoza, IQVIA RDS Czech Republic s.r.o., Prague, CZ
- 12:15 - 12:15 **169P - Impact of open-label design on patient-reported outcomes (PROs) data in randomized clinical trials of immuno-oncology (IO) agents in patients with advanced or metastatic cancer: A 10-year systematic literature review (SLR)**
A. Anota¹, A. Pozet², C. Lefevre³, H. Lemasson³, F.-E. Cotte³, S. Guertzider⁴, G. Mouillet⁵, G. Eberst⁴, E. Charton¹, V. Westeel⁵, ¹CHRU Besancon - Hopital Jean Minjot, Besancon,

FR, ²University Hospital of Besançon, Besançon, FR, ³Bristol-Myers Squibb, Rueil-Malmaison, FR, ⁴CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ⁵CHRU Besançon - Hopital Jean Minjoz, Besançon, FR

- 12:15 - 12:15 **170P - Anti- α 5B1; gal antibodies in the context of blood group and stool and tumour-adjacent microbiome in colorectal cancer patients**
I. Selingerova¹, E. Budinska², B. Zwinsova², B. Mazalova¹, B. Bencsikova¹, D. Valik³, L. Zdrzilova Dubska¹, ¹Masaryk Memorial Cancer Institute, Brno, CZ, ²Masaryk University, Faculty of Science, Brno, CZ, ³Masaryk University, Faculty of Medicine, Brno, CZ
- 12:15 - 12:15 **171P - Treatment (tx) patterns of patients with advanced renal cell carcinoma (aRCC) receiving first-line (1L) tx: Results from a cross-sectional real-world study**
G. Zanotti¹, R. Kim², S. Krulewicz³, J. Hall⁴, A. Leith⁴, A. Bailey⁴, F. Liu⁵, M. Kearney⁶, ¹Pfizer Inc - USA, New York, US, ²Pfizer Inc., New York, US, ³Pfizer Inc - USA, Colleagueville, US, ⁴Adelphi Communications - Adelphi Group, Bollington, GB, ⁵EMD Serono, Inc., Rockland, US, ⁶Merck KGaA, Darmstadt, Germany, Darmstadt, DE
- 12:15 - 12:15 **172P - miR-486-5p counteracts the shedding of MICA/B and CD155 immune-ligands in TNBC patients**
A. Elkhoully, R. Youness, M. Gad, German University in Cairo, Cairo, EG
- 12:15 - 12:15 **173TiP - PECan study, imaging PD-L1 in cancer: A tool for measuring response to immunotherapy?**
D. Hughes¹, G. Chand², D. Josephs², M. Harries², S. Papa², J. Spicer², H.H. Ting³, V. Goh², G. Cook², ¹University College London Hospital UCLH NHS Foundation Trust, London, GB, ²King's College London, London, GB, ³NanoMab Technology Limited, Shanghai, CN

13:15 - 14:15	Type: Industry Satellite Symposium Title: Bristol-Myers Squibb - Building the future: Advances in immunotherapy Moderation: Dirk Jäger, DE	Room C
13:15 - 13:20	Welcome & Introduction <u>D. Jäger</u> , Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE	
13:20 - 13:40	Cancer immunotherapy in the clinic: Where are we today <u>S. Peters</u> , Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH	
13:40 - 14:00	Overcoming IO resistance: Going beyond PD-1 blockade <u>M. Maio</u> , Azienda Ospedaliera Universitaria Senese - Santa Maria delle Scotte, Siena, IT	
14:00 - 14:15	Conclusions and Q&A <u>D. Jäger</u> , Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE	
14:20 - 14:55	Type: Keynote Title: ESMO Award for Immuno-Oncology 2019 Moderation: Pedro Romero, CH; John Haanen, NL	Room A
14:20 - 14:20	DOI session	
14:20 - 14:50	Mechanisms of immunotherapy efficacy versus resistance <u>T. Gajewski</u> , The University of Chicago, Chicago, US	

15:00 - 16:30 **Type: Educational session** **Room A**
Title: Chest tumours: Updates
Moderation: Natasha Leighl, CA; Alessandra Curioni, CH

15:00 - 15:00 **DOI session**

15:00 - 15:20 **First line treatment of advanced NSCLC with no targetable alterations**
E. Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, US

15:20 - 15:40 **Neoadjuvant treatment of NSCLC with immunotherapy: Where are we now?**
S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

15:40 - 16:00 **Immunotherapy in SCLC: First and second-line approaches**
N. Leighl, Princess Margaret Cancer Center, Toronto, CA

16:00 - 16:20 **Immunotherapy for mesothelioma: What's new?**
S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB

16:20 - 16:30 **General discussion / Q&A**

15:00 - 16:30	Type: Educational session Title: Gastrointestinal cancers: Updates Moderation: Myriam Chalabi, NL; Josep Tabernero, ES	Room C
15:00 - 15:00	DOI session	
15:00 - 15:20	Consensus on MSI/MMR determination to select patients eligible for anti-PD1 therapies <u>A. Scarpa</u> , AOU Integrata Borgo Roma Verona, Verona, IT	
15:20 - 15:40	Immune therapeutics in gastroesophageal cancer <u>J. Tabernero</u> , Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES	
15:40 - 16:00	Immune therapeutics in HCC <u>B. Sangro</u> , Clinica Universidad de Navarra, Pamplona, ES	
16:00 - 16:20	Immune therapeutics in CRC (MSI and experimental approaches in MSS tumours) <u>M. Chalabi</u> , Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL	
16:20 - 16:30	General discussion / Q&A	
16:30 - 17:00	Type: Coffee break Title: Coffee break	Foyer ABC

17:00 - 18:30 **Type: Educational session** **Room A**
Title: Skin cancers: Updates
Moderation: Caroline Robert, FR; Paolo Ascierto, IT

17:00 - 17:00 **DOI session**

17:00 - 17:20 **Neoadjuvant immunotherapy for melanoma**
C. Blank, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL),
Amsterdam, NL

17:20 - 17:40 **Beyond immune checkpoint inhibitors**
A. Eggermont, Institut Gustave Roussy, Villejuif, FR

17:40 - 18:00 **Combination or sequence of immunotherapy and targeted therapy: Update**
P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

18:00 - 18:20 **New treatment approaches in advanced cSCC**
D. Schadendorf, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

18:20 - 18:30 **General discussion / Q&A**

17:00 - 18:30 **Type: Educational session** **Room C**
Title: Imaging and nuclear medicine
Moderation: Dirk De Ruyscher, NL; Roger Sun, FR

17:00 - 17:00 **DOI session**

17:00 - 17:20 **Engineered immune cells as highly sensitive cancer diagnostics**
I. Alam, Stanford University, Stanford, US

17:20 - 17:40 **Radiomics approach in relation to immunotherapy**
R. Sun, Institut Gustave Roussy, Villejuif, FR

17:40 - 18:00 **PET imaging to visualize immunotherapy**
E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL

18:00 - 18:20 **Role of innovative imaging in immunotherapy**
D. De Ruyscher, Maastricht University Medical Centre (MUMC)-MAASTRO clinic,
Maastricht, NL

18:20 - 18:30 **General discussion / Q&A**

13.12.2019

08:00 - 09:00 **Type: Collaborative** **Room**
Title: ESMO-CIRSE Collaborative session: Interventional oncology and **A**
immuno-oncology
Moderation: Thierry de Baere, FR; John Haanen, NL

08:00 - 08:00 **DOI session**

08:00 - 08:06 **Introduction**

T. De Baere, Institut Gustave Roussy, Villejuif, FR

08:06 - 08:18 **Locoregional delivery of immunotherapy**

L. Tselikas, Institut Gustave Roussy, Villejuif, FR

08:18 - 08:30 **Percutaneous ablation to stimulate tumor immunity**

B. Aarts, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

08:30 - 08:42 **Intra-arterial therapies and immune response**

R. Duran, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

08:42 - 08:54 **Intra-tumoral RECIST: The complexity of non-enestic response**

L. Schwartz, Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

08:54 - 09:00 **Conclusions and perspectives**

J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

08:00 - 09:00 **Type: Mini Oral session** **Room**
Title: Mini Oral session 2 **C**
Moderation: Marco Donia, DK; Pedro Romero, CH

08:00 - 08:00 **DOI session**

08:00 - 08:05 **20 - Biomarkers of immune switch induced by a novel anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in MATINS trial patients with advanced solid tumours**

M. Hollmén¹, R. Virtakoivu¹, P. Jaakkola², A. Minchom³, S. Jalkanen¹, M. Karvonen⁴, J. Mandelin⁴, J. Koivunen⁵, P. Bono⁶, ¹University of Turku Faculty of Medicine, Turku, FI, ²Helsinki University Hospital, Helsinki, FI, ³Royal Marsden Hospital, London, GB, ⁴Faron Pharmaceuticals, Turku, FI, ⁵Oulu University Hospital, Oulu, CH, ⁶Terveystalo, Helsinki, FI

- 08:05 - 08:10 **30 - A pre-existing inflammatory immune microenvironment predicts the clinical and immunological response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 peptide vaccination**
Z. Abdulrahman¹, N.F.C.C. De Miranda², M.I.E. Van Poelgeest², S.H. Van Der Burg²,
¹Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ²Leiden University Medical Center, Leiden, NL
- 08:10 - 08:15 **1300 - Association of long non-coding RNA biomarkers with clinically immune subtype and prediction of immunotherapy in patients with cancer**
Y. Yu¹, W. Zhang², A. Li², Y. Chen³, Y. Wang¹, Y. Zhang¹, Z. He¹, Q. Ou¹, R. Liu², E. Song¹,
H. Yao¹, ¹Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN,
²Guangdong Medical University, Zhanjiang, CN, ³The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN
- 08:15 - 08:20 **940 - Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data**
B. Gao¹, J. Goh², B. Markman³, M. Voskoboynik⁴, H.K. Gan⁵, J. Coward⁶, D. Palmieri¹, J. So⁷, T. Meniawy⁸, C. Chen⁹, X. Xiang⁹, J. Qiu⁹, Y. Xu¹⁰, L. Yang⁹, M. Millward¹¹,
¹Blacktown Cancer and Haematology Centre, Blacktown, AU, ²ICON Research, South Brisbane QLD, AU, ³Monash Health and Monash University, Victoria, AU, ⁴Nucleus Network, Melbourne, AU, ⁵Austin Hospital, Melbourne, AU, ⁶ICON Cancer Care, Brisbane, AU, ⁷Monash Health and Monash University, Melbourne, VIC, AU, ⁸The University of Western Australia, Perth, AU, ⁹BeiGene (Beijing) Co., Ltd., Beijing, CN, ¹⁰BeiGene (Shanghai) Co., Ltd., Shanghai, CN, ¹¹The University of Western Australia, Perth, AU
- 08:20 - 08:25 **950 - The immunoglobulin superfamily receptome defines cancer-relevant networks associated with response to immunotherapy**
N. Martinez-Martin, E. Verschueren, B. Husain, Genentech, Inc., South San Francisco, US
- 08:25 - 09:00 **Discussion led by Moderators**
P. Romero¹, M. Donia², ¹Ludwig Center for Cancer Research of the UNIL, Epalinges, CH, ²Herlev Hospital - National Center for Cancer Immune Therapy, Herlev, DK

09:10 - 10:40 **Type: Educational session** **Room A**
Title: Innovative technological development
Moderation: Pedro Romero, CH

09:10 - 09:10 **DOI slide**

09:10 - 09:30 **Artificial intelligence for digital tissue biomarker discovery in immune oncology**
G. Schmidt, Definiens AG, Munich, DE

09:30 - 09:50 **Development and commercialisation of a first-in-class chimeric antigen receptor T-cell product for large cell lymphoma**
J. Rossi, Kite Pharma, Inc., Santa Monica, US

09:50 - 10:10 **RNA vaccines for the treatment of solid cancers**
Ö. Türeci, BioNTech AG, Mainz, DE

10:10 - 10:30 **Probody therapeutics: Protease-activated antibody prodrugs for the treatment of cancer**
B. Zheng, CytomX Therapeutics, South San Francisco, US

10:30 - 10:40 **General discussion / Q&A**

09:10 - 10:40	Type: Educational session Title: Genitourinary cancers: Updates Moderation: Thomas Powles, GB; Cristina Suarez Rodriguez, ES	Room C
09:10 - 09:10	DOI session	
09:10 - 09:30	Combinations in front line renal cancer <u>C. Suarez Rodriguez</u> , Vall d'Hebron University Hospital, Barcelona, ES	
09:30 - 09:50	Immune therapy for prostate cancer <u>R. Jones</u> , Beatson West of Scotland Cancer Centre, Glasgow, GB	
09:50 - 10:10	Bladder cancer: New treatments and new biomarkers <u>T. Powles</u> , St. Bartholomew's Hospital, London, GB	
10:10 - 10:30	Immune therapy in non-metastatic bladder cancer <u>M. Van Der Heijden</u> , Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL	
10:30 - 10:40	General discussion / Q&A	
10:40 - 11:00	Type: Coffee break Title: Coffee break	Foyer ABC

11:00 - 12:30 **Type: Educational session** **Room A**
Title: Novel biomarkers and drugs
Moderation: Kevin Harrington, GB; George Coukos, CH

11:00 - 11:00 **DOI session**

11:00 - 11:20 **Novel engineered immune agonists for cancer immunotherapy**
P. Umana, Roche Glycart AG - Switzerland, Schlieren, CH

11:20 - 11:40 **Novel biomarkers for oncolytic virotherapy: Using transcriptomics to understand newcastle disease virus**
N. Durham, AstraZeneca, Gaithersburg, US

11:40 - 12:00 **Biomarkers in the era of combination therapies: Complexities and potential solutions**
Z.A. Cao, Merck Sharp & Dohme Corp. USA, Whitehouse Station, US

12:00 - 12:20 **Genomic biomarkers for immunotherapy in cancer**
V. Liebenberg, Illumina Inc., Berlin, DE

12:20 - 12:30 **General discussion / Q&A**

11:00 - 12:15 **Type: Proffered Paper session** **Room C**
Title: Proffered Paper session 2
Moderation: Lawrence Fong, US; John Haanen, NL

11:00 - 11:00 **DOI session**

11:00 - 11:15 **910 - A multi-center phase IIa trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC)**
M. Hidalgo¹, V. Semenisty², B. Bockorny³, E. Borazanci⁴, D. Von Hoff⁵, J. Feliu⁶, M. Ponz Sarvise⁷, D. Gutierrez Abad⁸, A. Peled⁹, O. Bohana-Kashtan¹⁰, Y. Gozlan¹⁰, E. Sorani¹⁰, M. Chaney¹¹, S. Kadosh¹², A. Vainstein¹⁰, T. Macarulla¹³, ¹CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES, ²Rambam Health Care Center, Haifa, IL, ³Beth Israel Deaconess Medical Center, Boston, US, ⁴HonorHealth Research Institute, Scottsdale, US, ⁵NDA Consulting Corp., Scottsdale, US, ⁶Hospita University of La Paz, Madrid, ES, ⁷Clinica Universitaria de Navarra, Pamplona, ES, ⁸Hospital de Fuenlabrada, ES, ⁹Hebrew University Hospital, Jerusalem, IL, ¹⁰BioLineRx Ltd, Modi'in-Maccabim-Re'ut, IL, ¹¹Merck & Co., Inc. - Upper Gwynedd Site, North Wales, US, ¹²StatExcellence Ltd, Nesher, IL, ¹³HOSPITAL VALL D'HEBRON, ES

11:15 - 11:30 **Invited Discussant 910**

L. Fong, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

11:30 - 11:45 **1290 - Resistance to immunotherapy is associated with high parenchymal PD1&&**

A. Lepletier De Oliveira¹, J. Madore¹, J. S. O'Donnell¹, R. L. Johnston¹, M. Eastgate², D. Mallardo³, P. Ascierto⁴, D. Massi⁵, B. Merelli⁶, M. Mandala⁶, J. S Wilmott⁷, T. Bald¹, J. Stagg⁸, B. Routy⁸, G. V. Long⁷, R. A. Scolyer⁷, N. Waddell¹, W. C. Dougall¹, M. W. L. Teng¹, M. Smyth¹, ¹QIMR Berghofer Medical Research Institute, Brisbane, AU, ²Royal Brisbane Clinical Unit, Brisbane, AU, ³Instituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, IT, ⁴Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁵University of Florence Medical School, Florence, IT, ⁶Papa Giovanni XXIII Hospital, Bergamo, IT, ⁷The University of Sydney, Sydney, AU, ⁸University of Montreal Hospital, Montreal, CA

11:45 - 12:00 **10 - Harmonization and standardization of panel-based tumour mutational burden (TMB) measurement: Real-world results and recommendations of the QuIP study**

A. Stenzinger¹, V. Endris², J. Budczies¹, S. Merkelbach-Bruse³, W. Dietmaier⁴, U. Siebolts⁵, J. Maas⁶, D.M. Merino⁷, M. Stewart⁷, J. Allen⁷, H. Glimm⁸, M. Thiemann⁹, D. Aust⁸, M. Hummel¹⁰, H. Moch¹¹, A. Jung¹², F. Haller¹³, W. Weichert¹⁴, M. Dietel¹⁰, ¹University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE, ²University Hospital Heidelberg, Heidelberg, DE, ³University Hospital Cologne, Köln, DE, ⁴University Hospital Regensburg, Regensburg, DE, ⁵University Hospital Halle, Halle, DE, ⁶Quality in Pathology GmbH, Berlin, DE, ⁷Friends of Cancer Research (FoCR), Washington, US, ⁸University Hospital Dresden, Dresden, DE, ⁹Hematopathology Hamburg, Hamburg, DE, ¹⁰Charité University Hospital, Berlin, DE, ¹¹University Hospital Zurich, Zürich, CH, ¹²University Hospital Munich (LMU), München, DE, ¹³University Hospital Erlangen, Erlangen, DE, ¹⁴University Hospital Munich (TUM), München, DE

12:00 - 12:15 **Invited Discussant 1290 and 10**

J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

**12:30 - 13:15 Type: Coffee break
Title: Lunch**

Foyer ABC

13:15 - 14:15	Type: Industry Satellite Symposium Title: Amgen - BiTE: Closing the gap between T cells and tumours	Room C
13:15 - 13:40	T-cell engaging immuno-oncology therapy: perspectives on BiTEs and CAR-Ts <u>M. Subklewe</u> , LMU Klinikum der Universität München, Munich, DE	
13:40 - 14:05	BiTEs in haematological malignancies and solid tumours: clinical experience and future potential <u>R.C. Bargou</u> , University of Würzburg, Würzburg, DE	
14:05 - 14:15	Q&A and closing remarks <u>M. Subklewe</u> , LMU Klinikum der Universität München, Munich, DE	
14:30 - 16:00	Type: Educational session Title: Artificial intelligence (AI) meets immuno-oncology Moderation: Thomas Powles, GB; Pedro Romero, CH	Room A
14:30 - 14:30	DOI session	
14:30 - 14:50	AI assisted-integrative view of the tumour microenvironment <u>T. Gajewski</u> , The University of Chicago, Chicago, US	
14:50 - 15:10	Genomics correlates of response to immunotherapy <u>N. Vokes</u> , Dana Farber Cancer Institute, Boston, US	
15:10 - 15:30	Computational biology of antigen processing and presentation: A key to personalised immunotherapy of cancer <u>D. Gfeller</u> , Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, CH	
15:30 - 15:50	AI in radiomics <u>Z. Bodalal</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL	
15:50 - 16:00	General discussion / Q&A	

14:30 - 16:00	Type: Educational session Title: Haematological malignancies: Updates Moderation: Markus Manz, CH; Judith Anne Shizuru, US	Room C
14:30 - 14:30	DOI session	
14:30 - 14:50	Clonal hematopoiesis <u>M. Manz</u> , University Hospital Zürich, Zurich, CH	
14:50 - 15:10	Engineered mAbs in haematological malignancies <u>H. Salih</u> , German Cancer Consortium, Tübingen, DE	
15:10 - 15:30	Academic development of CAR CIK-cells in B-cell neoplasia <u>A. Biondi</u> , Università degli Studi di Milano Bicocca - Facoltà di Medicina e Chirurgia, Monza, IT	
15:30 - 15:50	Precision hematopoietic stem cell replacement therapy <u>J.A. Shizuru</u> , Stanford University School of Medicine, Stanford, US	
15:50 - 16:00	General discussion / Q&A	
16:00 - 16:30	Type: Coffee break Title: Coffee break	Foyer ABC
16:30 - 18:00	Type: Educational session Title: Breast and gynaecological cancers: Updates Moderation: Lana Kandalaft, CH; Panagiotis Konstantinopoulos, US	Room A
16:30 - 16:30	DOI session	
16:30 - 16:55	Immunotherapy landscape in metastatic breast cancer <u>G. Curigliano</u> , Istituto Europeo di Oncologia, Milan, IT	
16:55 - 17:20	Personalised cancer vaccines in ovarian cancer <u>L. Kandalaft</u> , Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH	
17:20 - 17:45	Combining PARP inhibition and immunotherapy in ovarian cancer <u>P. Konstantinopoulos</u> , Dana-Farber Cancer Institute, Boston, US	
17:45 - 18:00	General discussion / Q&A	

16:30 - 18:00 **Type: Educational session** **Room C**
Title: Head & neck cancers: Updates
Moderation: Anthony Chan, HK; Kevin Harrington, GB

16:30 - 16:30 **DOI session**

16:30 - 16:50 **Update on current state of immune checkpoint inhibitors in H&N cancer**
A. Chan, The Chinese University of Hong Kong, Shatin, HK

16:50 - 17:10 **Oncolytic virus therapies for H&N cancer**
K. Harrington, Institute of Cancer Research ICR, London, GB

17:10 - 17:30 **Toll-like receptor agonists and other innate immune activators in H&N cancer**
E. Cohen, Moores Cancer Center - UC San Diego Health, La Jolla, US

17:30 - 17:50 **Radiation-mediated activation of immune responses in H&N cancer**
E. Deutsch, Institut Gustave Roussy, Villejuif, FR

17:50 - 18:00 **General discussion / Q&A**

14.12.2019

09:00 - 10:30	Type: Educational session Title: On the cross-talk endothelial cells: Immune cells in the tumor microenvironment Moderation: Pedro Romero, CH	Room A
09:00 - 09:00	DOI session	
09:00 - 09:20	Desmoplastic colorectal carcinoma <u>T. Petrova</u> , UNIL - University of Lausanne, Lausanne, CH	
09:20 - 09:40	Lymphatic endothelial cells as antigen presenting cells in tumour T-cell immunity <u>S. Hugues</u> , Université de Genève (UNIGE) - Centre Médical Universitaire (CMU), Geneva, CH	
09:40 - 10:00	Inducing high endothelial venules in cancer to enhance immunotherapy <u>G. Bergers</u> , VIB - Center for Cancer Biology, Leuven, BE	
10:00 - 10:20	Combining antiangiogenic and immune checkpoint blockade <u>J. Bedke</u> , University of Tuebingen, Tübingen, DE	
10:20 - 10:30	General discussion / Q&A	

09:00 - 10:30	Type: Educational session Title: Brain tumours: Updates Moderation: Michael Weller, CH; Enrico Franceschi, IT	Room C
09:00 - 09:00	DOI session	
09:00 - 09:20	Biomarkers of response to checkpoint inhibition in glioblastoma <u>E. Franceschi</u> , Ospedale Bellaria, Bologna, IT	
09:20 - 09:40	Immune checkpoint inhibition for glioblastoma: Update on the first three CheckMate trials <u>M. Weller</u> , Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH	
09:40 - 10:00	Peptide based vaccination therapy for glioblastoma <u>P.-Y. Dietrich</u> , Hôpitaux Universitaires de Genève - HUG, Geneva, CH	
10:00 - 10:20	Immune checkpoint inhibition for patients with brain metastasis: Patient selection and assessment of benefit <u>E. Le Rhun</u> , Roger Salengro Hospital, Lille, FR	
10:20 - 10:30	General discussion / Q&A	
10:30 - 11:00	Type: Coffee break Title: Coffee break	Foyer ABC

11:00 - 12:30	Type: Educational session Title: Tumour antigens and neoantigens Moderation: Andrew Furness, GB; George Coukos, CH	Room A
11:00 - 11:00	DOI session	
11:00 - 11:20	State of the art: Neoantigens, T-cell recognition and tumour rejection <u>Y. Samuels</u> , Weizmann Institute of Science, Rehovot, IL	
11:20 - 11:40	Beyond high TMB: Neoantigen landscape in ovarian cancer <u>G. Coukos</u> , Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, CH	
11:40 - 12:00	Immunoediting: Anti-tumour immunity and tumour evolution <u>R. Rosenthal</u> , UCL - University College London, London, GB	
12:00 - 12:20	Translation: Clinical application of neoantigen-reactive T-cells <u>A. Gros</u> , Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES	
12:20 - 12:30	General discussion / Q&A	

11:00 - 12:30	Type: Educational session Title: Reducing costs by decreasing either dose or frequency of dosing Moderation: Daniel Goldstein, IL; John Haanen, NL	Room C
11:00 - 11:00	DOI session	
11:00 - 11:20	Opportunities to reduce dosing frequency of checkpoint inhibitors <u>D. Goldstein</u> , Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL	
11:20 - 11:40	Pharmacokinetic modelling and therapeutic drug monitoring <u>C. Peer</u> , National Cancer Institute, Bethesda, US	
11:40 - 12:00	Dose reductions from the perspective of the health care payer <u>P. Clark</u> , National Health Service- Cancer Drug Fund, London, GB	
12:00 - 12:20	Dosing reductions of checkpoint inhibitors in lung cancer <u>B. Piet</u> , Radboud University Medical Center, Nijmegen, NL	
12:20 - 12:40	General discussion / Q&A	
12:30 - 12:40	Type: Educational session Title: Meeting close	Room C
12:40 - 13:15	Type: Coffee break Title: Light lunch	Foyer ABC